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1 
INTRODUCTION 
GENERAL INTRODUCTION 
Inositol polyphosphate 4-phosphatases (IP4Ps) are enzymes that catalyze the 
hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate 
(PtdIns(3,4)P2) to form phosphatidylinositol 3-phosphate (PtdIns(3)P) (1,2). These enzymes 
have been shown to play a role in a wide variety of processes including neuronal 
development, megakaryocyte differentiation and the neutrophil oxidative burst (3,4,5). 
BLAST searches for proteins similar to IP4Ps led to the identification of two proteins, 
P-Rexl and P-Rex2. Besides sharing similarity to IP4Ps at the C-terminus, these proteins had 
a Dbl homology (DH) domain followed by a pleckstrin homology (PH) domain at its 
N-terminus. These tandem DH/PH domains are signature sequences found in the Dbl family 
of guanine nucleotide exchange factors (GEFs). The occurrence of a Dbl family GEF domain 
along with an IP4P-like domain had previously never been seen to occur simultaneously in a 
single protein. 
Human P-Rexl was recently isolated from neutrophils, the tissue in which it is mainly 
expressed (6,7). The protein consists of 1659 amino acids with a complex and unusual 
domain architecture consisting of N-terminal DH/PH domains, two DEP domains, two PDZ 
domains and a C-terminal IP4P-like domain. DEP domains are domains of unknown function 
that have been found in a large number of proteins involved in the regulation of G protein 
signaling (8,9). PDZ domains are protein-protein interaction domains that bind to the 
C-terminus of membrane proteins or internal domains of proteins with a constrained structure 
(10,11). However, despite its similarity with IP4Ps, phosphatase function could not be 
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identified for P-Rexl (6). P-Rexl functions as a Rac specific GEF whose activity was 
stimulated directly and synergistically by phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)Ps) and the (3y subunits of heterotrimeric G proteins both in vitro and in vivo. 
However, the domain/s responsible for binding these effectors have not been identified. 
Moreover, the mechanism by which this protein is regulated and recognizes its substrate Rac, 
has also not been uncovered (6). P-Rexl plays a major role in the neutrophil oxidative burst 
by activating Rac a component of the NADPH oxidase complex (6). 
In this thesis, I describe the cloning and biochemical characterization of human 
P-Rex2, and its alternate splice variant P~Rex2B. Characterization of both these proteins 
revealed that they are Rac specific GEFs whose GEF activity is conditional on the presence 
of either PtdIns(3,4,5)P3 or GJ3y subunits in vitro and in vivo. Furthermore, I describe the 
unusual way in which P-Rex2 interacts with its substrate Rac, and provide evidence for an 
intra-molecular interaction within the protein involving the PDZ, DEP and PH domains. 
Taken together, these studies provide structural insights into the mechanism of regulation and 
substrate (Rac) recognition of the P-Rex family of proteins. 
THESIS ORGANIZATION 
This dissertation consists of six chapters: a general introduction, followed by four 
manuscripts and an overall conclusion. The literature review section that immediately 
follows this will provide the necessary background information and the current status of what 
is known about the IP4Ps, Rho family G proteins, Dbl family of GEFs, P-Rexl, DEP 
domains and PDZ domains. Chapter Two, which has been submitted for publication to the 
Journal of Biological Chemistry, deals with the cloning and characterization of P-Rex2A. 
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The main findings of this paper are that P-Rex2A is a Rac specific GEF whose activity is 
conditional on the presence of Ptdlns(3,4,5)?3 or G (By subunits in vitro and in vivo. The PH 
domain of P-Rex2 was shown to be able to bind to both these effectors. Phosphatase activity 
however, could not be demonstrated for this protein. Chapter Three, which has been 
submitted for publication to the Biochemical Journal, reveals the biochemical nature of 
P-Rex2B, an alternate splice variant of P-Rex2 that lacks the IP4P-like domain. 
Characterization of this protein brought to light the novel phosphoinositide lipid binding 
capability of the DEP domains of P-Rex2. Moreover, comparison between the two forms of 
P-Rex2 showed that the IP4P-like domain does not influence the GEF activity of P-Rex2. 
Chapters Four and Five are manuscripts in preparation for submission to the Journal of 
Biological Chemistry. Chapter Four explores the details of the interaction between P-Rex2 
and its substrate Racl. The results of this study reveal a surprising and novel role in substrate 
recognition for the PH domain of the Dbl family GEF P-Rex2. Chapter Five gives a glimpse 
into the three dimensional architecture of P-Rex2. An intra-molecular interaction between the 
PDZ domains, the DEP domains and the PH domain obscure the Racl binding site on 
P-Rex2, thereby providing an explanation for the inactivity of P-Rex2 in the absence of 
effectors. The conclusions chapter includes a summary of the research work, future directions 
of study and the implications of this work in the field of cellular signaling. 
LITERATURE REVIEW 
Signaling pathways within the cell are wide and varied. Over the years simple linear 
signaling pathways have evolved to become the complex web known today. Two such 
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pathways that have undergone rapid development over the past few decades are the 
phosphoinositide signaling pathway and the G protein mediated signaling pathway. 
Phosphoinositide Signaling 
Phosphatidylinositol (Ptdlns) is a versatile signaling molecule within the cell. The 
head group of this lipid can be phosphorylated at the 3,4 and 5 positions either singly or at 
multiple positions to give rise to seven different forms of the molecule (12,13). Regulating 
the activity of the kinases that phosphorylate these lipids and the phosphatases that 
dephosphorylate them tightly controls the intracellular levels of these lipids. The levels of 
these lipids vary widely with Ptdlns being the most abunduntant (10% of the total lipids in 
eukaryotic cell membranes), followed by phosphatidylinositol 4-phosphate (PtdIns(4)P) and 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)Pz). Phosphatidylinositol 3,4-bisphosphate 
(PtdIns(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate (Ptdlns(3,4,5)P^) are minor 
components of the cell and make up less than 0,25% of the lipids (12,14). However the levels 
of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 can surge following cellular stimulation, although they 
probably never match the levels of PtdIns(4)P or PtdIns(4,5)Pz (14). There is also widespread 
variation in the distribution of these lipids within the cell as phosphatidylinositol 3-phosphate 
(PtdIns(3)P) seems to be concentrated on early and multi-vesicular endosomal membranes 
within the cell (15). Lipid binding modules within proteins like the pleckstrin homology (PH) 
domains, C2 domains, phox homology (PX) domains, and FYVE domains bind to these 
phosphoinositide lipids and localize the proteins to specific intracellular locations within the 
cells (16). 
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Phosphoinositide Kinases 
Phosphoinositide kinases are divided into categories depending on the specific 
hydroxy! group in the inositol ring that is being phosphorylated, as phosphoinositide 
3-kinases (PI3Ks), phosphoinositide 4-kinases (PI4Ks) and phosphoinositide 5-kinases 
(PI5Ks) (17). PI3Ks phosphorylate the 3-position phosphate of Ptdlns, PtdIns(4)P and 
PtdIns(4,5)P2, to generate PtdIns(3)P, PtdIns(3,4)Pz and PtdIns(3,4,5)Ps. PI3Ks are further 
subdivided into three classes, Ia and Ib, II and III based on their structure, substrate 
specificity and mode of activation (18). They are downstream of several growth factor 
receptors like platelet derived growth factor (PDGF), and are involved in a wide variety of 
functions, including regulation of cell growth and differentiation, actin cytoskeletal network, 
apoptosis, chemotaxis and neutrophil oxidative burst (18,19). The enzyme PIKfyve is a 
phosphoinositide 5-kinase that synthesizes phosphatidylinositol 5-phosphate (PtdIns(5)P) and 
phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P%) (20). The levels of these lipids are 
elevated when yeast and mammalian cells are subjected to osmotic stress, suggesting a role 
for these enzymes in osmotic stress response pathways (21,22). 
Phosphoinositide Phosphatases 
Inositol lipid phosphatases can be classified into two groups: the CX5R family and the 
type II 5-phosphatase family depending upon signature sequences present within their active 
site (12). The CX5R family of phosphatases are metal ion independent phosphatases which in 
addition to inositol phosphatases also include protein phosphatases like tyrosine 
phosphatases, dual specificity phosphatases and low molecular weight phosphatases 
(23,24,25). The structure of several of these phosphatases have been solved (25,26,27,28). 
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The CX5R motif forms a loop (P loop) at the base of the active site pocket (25). The walls of 
the pocket are made from the backbone and side chain residues of the P loop, the "WPD" 
loop and the "Tl" loop. The phosphatase reaction occurs in two steps. First the cysteine of 
the CX5R motif acts as a nucleophile accepting the phosphate moiety to form a phospho-
enzyme intermediate. A conserved aspartic acid which islocated in the "WPD" loop assists in 
the cleavage of the bond by protonating the leaving group. The catalytic cycle is completed 
by activating a water molecule by the same aspartic acid residue which now acts as a 
catalytic base. The phosphate group is transferred to the water molecule restoring the enzyme 
back to its original state (29). It has been suggested that the depth of the active site pocket is 
an important determinant of the substrate specificity (25). The shallow pocket of VHR allows 
both phospho-tyrosine and phospho-serine/threonine residues to reach the catalytic cysteine 
at the bottom of the active site pocket, while the deeper PTE IB pocket allows only phopho-
tyrosine to reach (28). Compared to the active site of protein phosphatases, the active site 
pocket of PTEN and MTMR2, which are inositol 3-phosphatases, are wider and deeper to 
accommodate the larger phosphoinositol substrates (25,26). The "WPD" loops of PTEN and 
MTMR2 unlike that of protein phosphatases, are not flexible and do not undergo 
conformational changes upon substrate binding (25,26). Moreover, the "WPD" loop of 
MTMR2 differs from that of other phosphatases in that it does not contain the catalytic acid. 
In fact MTMR2 is thought to have a novel mechanism of hydrolysis by employing the 
aspartic acid within the CX5R motif itself as the catalytic acid (26). The CX5R motif (C-
R/K125"A-G-K128-G-R) of PTEN has two basic residues (Lys-125 and Lys-128) in its center. 
These residues along with the His-93 of the "WPD" loop give the active site pocket a highly 
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basic character. This is consistent with the highly negative PtdIns(3,4,5)P3 substrate and with 
its affinity for highly acidic polypeptide substrates (25). 
Inositol polyphosphate 4-phosphatases (IP4Ps), hydrolyze the 4-position phosphate of 
PtdIns(3,4)P2 to generate PtdIns(3)P (1,2). They are characterized by the presence of an 
active site CX5R consensus sequence 'CKSA/GKDRT' (2). There are two mammalian forms 
of the enzyme (Type I and Type II), which share 37% identity at the amino acid level (2). 
Alternate splicing at the C-terminus can generate proteins with either hydrophilic (Type la 
and Type lia) or hydrophobic (Type 1(3 or Type 11(3) ends (2). Unlike the a forms of the 
enzyme however, the |3 forms were catalytically inactive (2). The genes for human IP4P 
Type I and Type II has been localized to chromosome 2ql 1.2 and 4q28.1-q31.1 respectively 
(30). The open reading frame for human Type I gene is encoded by 25 exons, which are 
spread across -67 kb of DNA. Generation of the Type la isoforms (ai, «2, cc3) involves the 
use of exons 15,16 and 17. While Type Ia2 is generated by splicing together exons 15 and 
17, the generation of Type Iaj and Type Ia3 takes place in an unusual way by differential 
splicing involving the use of alternate 5-GU sites within exon 15. These isoforms of IP4P 
differ widely in their expression pattern with Type Iai being the major form in brain and 
Type Ia3 being the major form in platelets, Jurkat T cells and megakaryocytes (30). IP4P 
homologues have also been identified in Drosophila, C. elegans, and bacteria like 
Salmonella (SopB) and Shigella (IpgD) (31,32). Comparison of the bacterial IP4Ps to the 
mammalian form of the protein showed that apart from the CX5R active site motif, they share 
little similarity at the amino acid level. Moreover, these bacterial enzymes have relatively 
low specific activity and were able to hydrolyze several different phosphoinositide substrates 
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unlike their mammalian counterparts. Furthermore, the preferred substrates of SopB and 
IpgD were PtdIns(3,4,5)Ps and Ptdlns(4,5)?2 respectively, rather than the mammalian IP4P 
substrate PtdIns(3,4)Pz. These bacterial enzymes are virulence factors that function within 
the infected mammalian cells. IP4Ps are involved in a wide variety of processes within the 
cell including platelet aggregation, neuronal development and megakaryocyte differentiation 
(3,4,33). Intriguingly, IP4Ps are also involved in the neutrophil oxidative burst (5). IP4P was 
shown to regulate the NADPH oxidase complex in vitro by catalyzing the production of 
PtdIns(3)P, which recruits p40phox to the complex via its PX domain (5). 
G protein Signaling 
G proteins consist of two major classes: Heterotrimeric G proteins and the Ras 
superfamily of small G proteins. The heterotrimeric G proteins are signal transducers that 
communicate signals from a wide variety of molecules including hormones, 
neurotransmitters and chemokines (34). The signals are received by receptors having seven 
transmembrane regions that activate the G protein, which then routes the signal to specific 
intracellular signaling pathways. These G proteins have three subunits, a, (3 and y, with 
signals being propagated by both the a subunit as well as the (3y dimer (35). Currently there 
are twenty Ga, six G(3 and twelve Gy subunits that have been identified (35). The Ras 
superfamily of small G proteins consists of over 60 family members which can be subdivided 
into five major families: Ras, Rho, Ran, Rab and Arf (36). 
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Rho Subfamily of Small G proteins 
Rho family of G proteins are members of the Ras superfamily of proteins (36). They 
act as molecular switches within the cell that are 'on' when bound to GTP and 'off when 
bound to GDP. Their activity within the cell is very tightly regulated by guanine nucleotide 
exchange factors (GEFs), GTPase activating proteins (GAPs) and guanine nucleotide 
dissociation inhibitors (RhoGDIs). They are activated by GEFs, which exchange GDP for 
GTP and are inactivated by GAPs, which accelerate the rate of GTP hydrolysis. RhoGDIs 
bind to the GDP and GTP bound forms of the G protein and is thought to control the 
intracellular localization of the protein (37). 
The Rho sub-family of proteins consists of 20 members to date (38). Among the Rho 
family members, Rho A, Cdc42 and Racl are the most widely studied and well characterized. 
A characteristic feature of the Rho subfamily of proteins is the presence of an insert domain 
between the fifth (3 strand and fourth a helix in the GTPase domain (39). The Rho-subfamily 
of proteins share 40-95% sequence identity within the family and are grouped together based 
on their sequence similarity into Rac-like, RhoA-like, Cdc42-like, RhoBTB-like and Rnd-
like clusters (38,39). The Rac-like cluster consists of four proteins: Racl, Rac2, Rac3 and 
RhoG. Racl, 2 and 3 share 88% identity with each other with differences being mainly 
restricted to the C-terminal 15 amino acid residues (40). They differ in their expression 
pattern with Racl being ubiquitous, Rac2 being expressed mainly in haematopoetic cells and 
Rac3 being expressed mainly in brain tissue. Racl also undergoes alternate splicing to 
generate Rac lb. Rac lb behaves as a constitutively activated form of the protein as it has 
decreased GTPase activity and does not bind to RhoGDIs. It has been found to be associated 
with several cancers including breast and colon cancer. RhoG and Racl share about 72% 
identity at the amino acid level. RhoG is also expressed ubiquitously however its signaling 
processes within the cell are less clearly defined. Most Rho family members also have a 
C-terminal CAAX motif, which is modified by a geranylgeranyl moiety (39). These G 
proteins stepped out from under the shadows of the Ras superfamily in the early 80s when it 
was shown to mediate dramatic changes in the actin cytoskeletal network (41). Activation of 
Racl leads to the formation of membrane ruffles or lamellipodia, activation of Cdc42 leads 
to the formation of microspikes or fillopodia, and activation of RhoA leads to the formation 
of stress fibres (41). They have also been shown to be involved in a wide variety of processes 
including cell migration, differentiation, gene expression, proliferation and the neutrophil 
oxidative burst (36,42,43). 
Dbl Family of Guanine nucleotide exchange factors. 
The Dbl family of GEFs catalyze nucleotide exchange on the Rho subfamily of G 
proteins (44,45). Dbl was originally isolated as an oncogene from a diffuse B cell lymphoma 
(46). Since then its 300 amino acid characteristic sequence has been identified in -60 
mammalian proteins, making this one of the largest family of oncogenes (47). This 300 
amino acid sequence is subdivided into a Dbl homology (DH) domain followed by a 
C-terminal pleckstrin homology (PH) domain). However, some Dbl family members which 
have a PH domain that is located N-terminal to the DH domain have also been recently 
identified (48,49). Beyond the DH/PH domains, Dbl family members share little sequence 
similarity to each other and have been shown to contain a myriad of other domains including 
SH2, SH3, RasGAP, PDZ and additional PH domains (44). 
The DH domain consist of -200 amino acids and is the catalytic domain. Within the 
DH domain are three highly conserved regions referred to as conserved regions 1, 2 and 3 
(CRI, CR2 and CR3). The structure of several Dbl family members has been solved 
(50,51,52). It consists of an elongated helical bundle, with the CRI, CR2 and CR3 forming 
long helices that pack together to form the core of the module (51). The PH domain consists 
of -100 amino acids and is a lipid binding module that is found in several signaling 
molecules (53,54,55). It consists of a seven-stranded 3 sandwich that is capped on one end by 
a C-terminal a helix. The ^-strands are joined by loops of variable length and structure 
(56,57,58). The DH and PH domains together form an 'L' shaped structure. However, as the 
region between the DH and PH domains is poorly conserved within Dbl family members, the 
orientation of the PH domain with respect to the DH domain varies widely (59). 
The phosphoinositol lipid binding property of PH domains are well documented (60). 
The crystal structures of PH domains in complex with lipids have shown that basic residues 
located within the (31(32 loop, and the (36(37 loop primarily determines the specificity of the 
interaction (61,62,63). PH domains vary widely in their specificity and affinity of interaction 
with phosphoinositide lipids. Most Dbl family PH domains however have weak affinity and 
poor specificity for phosphoinositide lipids (64). PH domains of some proteins have also 
been shown to interact with proteins. The PH domains of ^-adrenergic receptor kinase 
((3-ARK), and Bruton's tyrosine kinase (Btk) have been shown to interact with (3y subunits of 
heterotrimeric G proteins (65,66). Lipid or protein binding by these PH domains is thought to 
mediate localization of the proteins in which they are found (54). 
The position of the PH domain in different proteins is generally not conserved. The 
association of the PH domain with the DH domain in all Dbl family GEFs therefore suggests 
a functional interdependence between these two modules (64). Emerging evidence suggests 
that these PH domains may have a multi-functional role. While the PH domain of some Dbl 
family members like Dbl and Lsc have been shown to mediate intracellular localization of 
the protein, deletion of the PH domain of other Dbl family members likeTiaml have no 
effect on its localization (67,68,69). Although the DH domain is the minimal catalytic unit, 
the DH/PH domain of Trio was a 100 fold more active than the DH domain alone (51). 
Binding of phosphoinositide lipids by the PH domain have been shown to modulate the 
activity of the DH domain of Sos, Vav, Tiaml and P-Rexl (70,71,6). The PH domain of Dbs 
interacts with its GTPase substrate Cdc42 and assists in guanine nucleotide exchange (59). 
The PH domain of Dbs was also recently shown to be an effector for GTP bound Racl (72). 
Activation of Dbl family GEFs in vivo lead to the activation of specific G protein 
signaling pathways (36). This specificity hinges on the ability of the GEFs to discriminate 
among the different G proteins present within the cell. Elucidation of the determinants of 
specificity of interaction between Dbl family GEFs and their cognate Rho GTPases is 
therefore of critical importance and has recently been an area of intense investigation 
(59,73,74,75,76). Dbl family members vary widely in their substrate specificity. GEFs like 
Tiaml and Trio catalyze exchange only on Racl (77,78), Dbs and Dbl are able to activate 
both Cdc42 and RhoA (79,80), while Vavl and Vav2 catalyze exchange on RhoA, Racl and 
Cdc42 (81). The structural basis for this recognition process is only beginning to be 
understood (73). The crystal structures of the Racl-Tiaml, Cdc42-Dbs, RhoA-Dbs and 
Cdc42-Intersectin (ITSN) complexes show that the CRl and CR3 regions of the DH domain 
of the GEF makes extensive contact with the (32(33 strands of the GTPases (73,76). These 
regions were therefore predicted to determine the specificity of these interactions. Based on 
these crystal structure complexes, Trp 56 of Racl, was isolated as one of the critical residues 
for recognition by Rac specific GEFs. This residue was recognized by a conserved Ile (1187 
in Tiaml), in the DH domain of all Rac specific GEFs. Mutation of the Trp 56 residue to 
Phe, the corresponding residue in Cdc42, was sufficient to abolish binding by Tiaml (75). 
Moreover, this mutant Racl could now be recognized by ITSN, a Cdc42 specific GEF. 
Conversely, substitution of Phe 56 of Cdc42 with Trp, allowed recognition by the Rac 
specific GEFs Tiaml, Trio and GEF-H1 (82). Furthermore, substitution of Leu 1736 of ITSN 
with lie (the corresponding residue in Tiaml), allowed ITSN to catalyze exchange on Racl 
(74). The ability of Dbl family GEFs to discriminate between Rho family GTPases based on 
a single residue, although surprising, has been reported for other GTPase-GEF interactions. 
A Ras to Rapl mutation (Q70L) was sufficient to cause robust activation of Ras by a Rapl 
specific exchange factor C3G (83). While the above crystal structures have been successful 
in teasing apart some of the details of a few GEF interactions, it cannot explain the 
specificities of all Dbl family GEF-GTPase interactions (74). Moreover, the contributions of 
the PH domain in these interactions have remained completely unexplored. 
Although the DH/PH domain of several Dbl family members have been extensively 
characterized, the properties of the full-length protein are less documented. Although 
effectors like phosphatidylinositol lipids have been shown to regulate the activity of the 
DH/PH domain of several Dbl family GEFs like Vav, Sos and Dbs, studies on full-length Dbl 
family GEFs show that they have additional modes of regulation. The GEF activity of 
P-Rexl and pll4RhoGEF has been shown to be stimulated directly by G(3y subunits (6,84). 
Dbl family members like Tiaml, Dbl, Asef and Vav have N-terminal inhibitory domains 
(85,86,87,88). N-terminal truncation mutants of these Dbl family GEFs are constitutively 
active when expressed in vivo. pll5RhoGEF and Lbc have C-terminal inhibitory regions 
(89,90). In most cases however, the mechanism by which such inhibition is brought about is 
not well understood. 
P-Rexl 
P-Rexl (PtdIns(3,4,5)P3-dependent Rac exchanger) was isolated from neutrophils as 
a PtdIns(3,4,5)Ps dependent Rac GEF activity (6). It has an open reading frame that is 4980 
bp long with a start Met being preceded by a Kozak consensus sequence and a GC rich 5' 
end. However, it lacks an in frame upstream stop codon, leaving a small possibility that the 
start Met may not be the true start. The gene for human P-Rexl consists of 41 exons and is 
located on chromosome 20 at ql3.13, spread across -300 kb of DNA. It is mainly expressed 
in peripheral blood leukocytes and the brain as a major transcript of -6 kb. P-Rexl 
recombinant protein consists of 1659 amino acids with a predicted molecular mass of 185 
kDa. It has an unusual and complex domain architecture with an N-terminal DH/PH domain, 
two DEP domains and two PDZ domains. The C-terminus of P-Rexl shares significant 
similarity to inositol polyphosphate 4-phosphatases (IP4Ps). Despite its amino acid similarity 
with IP4Ps, phosphatase activity could not be demonstrated for P-Rexl. P-Rexl was shown 
to be a Rac specific GEF, whose GEF activity was stimulated directly and synergistically by 
PtdIns(3,4,5)Ps and G (By subunits. However, the domain/s responsible for binding these 
effectors have not been identified. Moreover, the mechanism by which this protein is 
regulated is also unclear. P-Rexl is thought to function as a coincident detector of both 
PtdIns(3,4,5)Ps and G(3y subunits thereby integrating signals from both PI3Ks and 
heterotrimeric G proteins (6,7). 
DEP domains 
DEP domains (named after Dishevelled, Egl-10 and Pleckstrin) are evolutionary 
conserved from bacteria to mammals (9). Although they have been found in a large number 
of proteins involved in the regulation of G protein signaling, their in vivo function remains 
largely unknown (8,9). The structures of the DEP domains of Dishevelled and Epac2 showed 
that they have a unique fold that is not shared by other proteins in the structural database 
(9,91). The core is formed by three oi-helices (HI, H2 and H3), a |3-hairpin 'arm' between HI 
and H2, and a two short ^-strands following H3. The tertiary structure is stabilized by 
extensive hydrophobic interactions between the three helices. The two most notable features 
of this structure are the (3-hairpin 'arm' and a cluster of basic residues located on the surface 
of this domain. The (3-hairpin 'arm' has a strong electric dipole associated with it, a feature 
that is common in protein-protein docking interfaces (9). The cluster of basic residues on the 
surface of Dishevelled has been speculated to interact with negatively charged membrane 
lipids (91). The DEP domains of several other proteins including Epac, RGS9 and EGL-10, 
have been shown to mediate membrane association (92,93,94). However, the in vivo ligand/s 
for this domain, protein and/or lipid, has not been established. Moreover, as the (3-hairpin 
'arm' and the basic cluster are located on opposite surfaces of the domain, it is feasible that 
the DEP domain may interact simultaneously with both proteins and lipids (9). 
PDZ domains 
PDZ domains were originally identified as -90 amino acid sequence repeats in 
proteins (postsynaptic density 95, PSD95; the Drosophila sepate junction protein disc-large, 
Dig and the tight junction protein ZO-1) (10). PDZ domains were also referred to as DHR 
(DLG homology region) or GLGF repeat (after a signature Gly-Leu-Gly-Phe sequence in the 
domain). They are among the most abundant and widespread protein domains and have been 
identified in proteins from bacteria (307 proteins), plants (33 proteins), Ceanorhabditis 
elegans (92 proteins), Drosophila melanogaster (131 proteins) and Homo sapiens (over 400 
proteins). They are surprisingly rare in yeast with only three proteins in 
Schizosaccharomyces pombe and two in Saccharomyces cerevisiae (10,11). They function as 
protein-protein interaction modules and have been shown to bind to the C-terminal ends of 
partner proteins, which are often the cytoplasmic tails of transmembrane receptors and 
channels (10). The crystal structure of several PDZ domains has been solved. It consists of a 
globular structure with six ^-sheets and two a-helices (95,96). The PDZ domains found in 
bacteria and plants have a similar overall tertiary structure, however they have a different 
topology. Specifically, the PA strand that is derived from the N-terminal sequences in 
conventional PDZ domains is formed from the C-terminus of the PDZ-like domain of the 
photosystem IID1 C-terminal protease and Tsp protease from Escherichia coli (97,98). 
Peptide ligand binding occurs in the groove that is formed between the second beta (PB) 
strand and the second alpha (ccB) helix. Specifically, the peptide serves as an extra 3-strand 
that is added onto the edge of the pre-existing P-sheet within the PDZ domain. Residues at 
the 0 and -2 position of the peptide critically determine the binding specificity of PDZ 
domains, although residues at the -1 and -3 position and those further upstream also 
contribute to the binding. The backbone amides from the 'GLGF' sequence are also involved 
in hydrogen bonding with the free carboxylate residue and serve to cap the peptide-binding 
groove (10,11). Apart from binding C-terminal peptides, PDZ domain mediated recognition 
of non C-terminal motifs has also been discovered (10,11). The best example of this kind of 
interaction is that between the PDZ domains of nNOS and PSD95 or syntrophin (99). The 
PDZ domain of nNOS has C-terminal 30 residue extension that folds into a (3-hairpin 
structure. This (3-hairpin docks into the peptide-binding groove mimicking the peptide ligand 
through its P0 and P„2 pocket interactions (99). The PDZ7 domain of GRIP1 has a closed 
peptide-binding groove that is too narrow for conventional peptide interactions. Binding to 
GRASP-1 by the PDZ7 domain of GRIP1 was shown to occur through a large solvent-
exposed hydrophobic surface (100). A fascinating feature of PDZ domain containing proteins 
is that they often contain multiple PDZ domains (up to 13 in MUPP1 protein). These multiple 
PDZ domain containing proteins like the post-synaptic density protein, PSD95 and InaD of 
Drosophila serve as scaffolding and organize large protein signaling complexes (10). PDZ 
domains have also been shown to play a regulatory role. HtrA2/Omi is a mitochondrial serine 
protease in mammals that plays an important role in programmed cell death. Access to the 
active site of the protease is restricted by the C-terminal PDZ domain which packs against 
the protease domain through van der Waals contacts. Peptide binding by the PDZ domain of 
HtrA2 is thought to expose the protease domain, thereby activating the protease (101). 
NADPH Oxidase Complex 
P-Rexl plays a major role in stimulating the neutrophil oxidative burst by activating 
Rac, a component of the NADPH oxidase complex. It is a major protein present within 
neutrophils, making up almost 0.1% of the cytosolic proteins. Antisense oligonucelotides 
directed against P-Rexl reduced endogenous P-Rexl expression and reactive oxygen species 
production by 40-45% within a neutrophil-like cell line in response to C5a (6). The NADPH 
oxidase system is a multi-protein complex consisting of two membrane bound proteins 
(gp9lphox and p22phox), three cytosolic proteins (p47phox, p67phox and p4(fhox), and the GTPase 
Rac (102,103). Rac is kept in an inactive state by binding to the cytosolic protein RhoGDI, 
which prevents the exchange of bound GDP. An additional GTPase Rapl A co purifies with 
the complex, however its function is not known and it is not required for the cell-free 
reconstitution of oxidase activity (103). Activation of the complex occurs by translocation of 
the cytosolic components to the membrane, thereby assembling the entire complex. The 
NADPH oxidase catalyzes the production of superoxide (O2 ) from oxygen and NADPH. The 
superoxide that is generated by this complex in neutrophils and other phagocytic leukocytes 
is directly microbicidal and is also converted into reactive oxygen derivatives, which 
synergize with toxic granule proteins to facilitate microbial killing (101). The NADPH 
oxidase system has also been found in non-phagocytic cells like endothelial cells, epithelial 
cells, vascular smooth muscle cells, skeletal muscle cells and in the ocular lens 
(104,105,106,107). These non-phagocytic NADPH oxidases are structurally related to, but 
are functionally distinct from the neutrophil oxidases. They have low constitutive activity, 
which can be upregulated in response to growth factor stimulation. The reactive oxygen 
species produced by these complexes are thought to serve a signaling role and is also 
implicated in oxidative damage (104). 
The focus of the Norris lab has been on understanding IP4Ps. Our database searches 
for proteins similar to IP4Ps led to the identification of two proteins: P-Rexl and its 
homologue, P-Rex2. This work documents the cloning and characterization of P-Rex2. It 
also explores the details of substrate (Racl) recognition and the mechanism of regulation of 
P-Rex2. 
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CLONING AND CHARACTERIZATION OF P-REX2: A GUANINE 
NUCLEOTIDE EXCHANGE FACTOR WITH AN INOSITOL 
POLYPHOSPHATE ^ -PHOSPHATASE LHCE DOMAIN 
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summary 
P-Rexl was isolated from neutrophils through its activity as a guanine nucleotide 
exchange factor (GEF) for Rac, where it plays a key role in stimulating neutrophil oxidative 
burst. We also identified P-Rexl and a second family member P-Rex2 using database 
searches for proteins similar to inositol polyphosphate 4-phosphatases (IP4Ps). P-Rexl and 
P-Rex2 share 55% identity at the amino acid level, and have the same unique multi-domain 
architecture that includes a Dbl family GEF domain, two DEP domains, two PDZ domains 
and an IP4P-like domain. Although related to IP4Ps by homology, P-Rex2 does not 
hydrolyze the IP4P substrate phosphatidylinositol 3,4-bisphosphate. Characterization of 
P-Rex2 confirms that the P-Rex proteins are Rac specific GEFs that have the unusual need 
for either phosphatidylinositol 3,4,5-trisphosphate or G(3y subunits for in vitro activity. 
Mutational analysis indicates that the domain responsible for these requirements is the 
pleckstrin homology domain of P-Rex2. P-Rex2 is capable of promoting the formation of 
membrane ruffles in PDGF stimulated NIH 3T3 cells, demonstrating that it is a Rac specific 
GEF in vivo. Ruffling was decreased by depleting D-3 phosphatidylinositol lipids through 
exposure of the cells to wortmannin, suggesting that phosphatidylinositol lipids regulate the 
intracellular activity of P-Rex2. These proteins therefore represent a physical link between 
regulation of small GTPase activity and phosphatidylinositol lipid signaling and may further 
collaborate with G protein coupled receptor signaling. 
1 Primary researcher and author. 
* Author for correspondence. 
INTRODUCTION 
The Rho subfamily of G proteins are members of the Ras superfamily. They serve as 
molecular switches, which are 'on' when bound to GTP and 'off when bound to GDP. Their 
activities within the cell are tightly controlled, and are activated by guanine nucleotide 
exchange factors (GEFs), which catalyze the exchange of GDP for GTP. The Rho subfamily 
consists of about 18 members to date, of which Rac, Rho and Cdc42 are the prototypical 
members (1). They play a major role in regulating the organization of the actin cytoskeleton 
within the cell and control diverse cellular processes such as migration, neurite extension, 
cellular differentiation, cell cycle progression and neutrophil oxidative burst (2,3,4). 
The Dbl family of GEFs catalyzes exchange on Rho family G proteins. Over 60 
mammalian Dbl family GEFs have been identified to date and they vary in their substrate 
specificity, with some GEFs being highly specific, while others are more promiscuous (5,6). 
They are characterized by the presence of a Dbl homology (DH) domain, followed by a 
pleckstrin homology (PH) domain. The DH domain is the catalytic domain and consists of 
-200 amino acids (7). The PH domain consists of -100 amino acids, and is a lipid binding 
module found in several signaling proteins (8). The invariant association of the PH domain 
with the DH domain in all Dbl family members however, suggests a unique role for these PH 
domains. While they have been shown to mediate cellular localization of some Dbl family 
GEFs, there is increasing evidence suggesting that lipid binding by the PH domain can also 
modulate the activity of the associated DH domain (9,10,11,12,13,14). The mechanistic 
details of this process are only beginning to be uncovered (13). PH domains of other proteins 
like Btk and PARK have also been shown to be involved in protein-protein interactions, and 
can bind to the (3y subunits of heterotrimeric G proteins (15,16). Among the Dbl family 
GEFs, only P-Rexl and pi 14Rho GEF have been shown to be directly activated by 
GPy subunits. However, the domain/s within these two proteins that are responsible for this 
interaction have not been identified (17,18). 
P-Rexl was purified from neutrophils as a phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)Ps) dependent Rac GEF activity (17). The GEF activity of P-Rexl was also 
shown to be stimulated by G(3y subunits. It is therefore thought to integrate signals from both 
phosphoinositide 3-kinases (PI3Ks) and heterotrimeric G proteins (17,19). P-Rexl is mainly 
expressed in neutrophils, where it serves to stimulate the production of reactive oxygen 
species by activating Rac, a constituent of the neutrophil NADPH oxidase complex (17). In 
addition to having an N-terminal DH/PH domain, P-Rexl has a C-terminal domain which 
shares significant amino acid similarity with inositol polyphosphate 4-phosphatases (IP4Ps). 
IP4Ps are enzymes that catalyze the hydrolysis of the 4-position phosphate of 
phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) to produce phosphatidylinositol 
3-phosphate (PtdIns(3)P) (20,21). Intriguingly, IP4P was also shown to regulate the NADPH 
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oxidase complex in vitro by catalyzing the production of PtdIns(3)P, which recruits p40p/l(W to 
the complex (22). Despite its amino acid similarity with IP4Ps, phosphatase activity could 
not be demonstrated for P-Rex 1. 
Our searches for proteins similar to IP4Ps lead to the identification of P-Rex2, a 
homologue of P-Rexl. In this report we show that P-Rex2 is a Rac specific GEF regulated by 
PtdIns(3,4,5)Ps and G(3y subunits. The domain responsible for the binding of these effectors 
was also evaluated and was shown to occur via the PH domain of P-Rex2. 
EXPERIMENTAL PROCEDURES 
Materials 
The DH/PH domains of Dbl was PGR amplified from human mammary cDNA 
library (CLONTECH), and cloned into the pcDNA3.1D V5-His-TOPO vector (Invitrogen). 
Wild type RhoA for bacterial expression was created by PGR amplification and cloned into 
the Smal/NotI sites of pGEX 4T-1 (Amersham Pharmacia Biotech). Phosphatidylinositol 3,5-
bisphosphate (PtdIns(3,5)P2), was obtained from Echelon Inc. Phosphatidylinositol 3-
phosphate (PtdIns(3)P), Stearyl-arachidonyl-PtdIns(3,4,5)P3 and PtdIns(3,4)P2 were from 
Maytreya Inc. Phosphatidylcholine (PtdCho), phosphatidylinositol (Ptdlns), phosphatidic 
acid (PA), phosphatidylseiine (PtdS), phosphatidylinositol 4-phosphate (PtdIns(4)P), and 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) were obtained from Avanti Polar 
Lipids Inc. Para-nitrophenolphosphate (pNPP), was from Sigma. Tritiated inositol 1,3,4,5-
tetrakisphosphate (Ins(l,3,4,5)P^) was obtained from American Radiolabeled Chemicals, Inc. 
The FITC-anti-mouse secondary antibody and Rhodamine-Phalloidin were from Molecular 
Probes. The anti-V5 mouse monoclonal antibody was from Invitrogen. 
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Cloning of human P-Rex2 
BLAST searches for sequences similar to inositol polyphosphate 4-phosphates 
revealed the presence of two overlapping partial EST clones (AK024079 and AK023049). 
Oligonucleotides were designed based on these sequences and a 4138 bp fragment 
encompassing the 3' end of the gene was amplified from a human mammary cDNA library 
(CLONTECH) by nested PGR reactions using gene specific oligonucleotides 5'-
GAGGAATGGCAGTCTCACATTG-3 ' (sense) and 5'-TGTCTAGTCCAGCATTCAGGAG­
S'(antisense) for round I and 5 ' -GGGTCC AACATC ACTGAC ACC-3 ' (sense) and 
5'-GCCTGCCTGGTTTCTTGGGAG-3 ' (antisense), for round II. Upstream sequence was 
obtained by 5'RACE reactions using a combination of library specific oligonucleotides and 
gene specific oligonucleotides 5 ' -GCGCCGCGCTGCGCACCGCCG-3 ' (sense) and 
5 '-TTCAATGTGAGACTGCCATTCCTC-3' (antisense). The cDNA for P-Rex2 is 4903 bp 
(GenBank accession # AY508996), and was cloned into pcDNA3.1V5/His TOPO vector for 
mammalian expression and into the Ndel/NotI sites of the pAcGHLT-A vector (BD 
Biosciences Pharmingen) for expression in Sf9 cells by PCR. The DH domain (residues 22 to 
231), the PH domain (residues 241 to 370) and the DH/PH domains of P-Rex2 (residues 22 
to 370) were cloned into pcDNA3.1V5/His TOPO vector by PCR. The PH domain was also 
cloned into the Ndel/NotI sites of pAcGHLT-A vector for expression in Sf9 cells. 
Northern Blotting 
A human multi-tissue northern blot (CLONTECH) was probed with a random primed 
labeled P-Rex2 fragment (nucleotide 1158 to 2254) using Express Hyb (CLONTECH) 
according to the manufacturers instructions. 
Expression and purification of proteins 
GST and GST-tagged Racl, RhoA and Cdc42 were expressed and purified from 
Escherichia coli as described elsewhere (23). GST-tagged P-Rex2 and GST-tagged PH 
domain of P-Rex2 were expressed and purified from Sf9 cells as described earlier (17). 
Complex Formation Assay 
The complex formation assay was performed essentially as described (24). The 
DH/PH domains of P-Rex2 and Dbl were labeled with [35]S Met using rabbit reticulocyte 
lysate coupled transcription translation system (Promega) for 90min at 30°C in a total 
reaction volume of lOfxl, as per the manufacturers instruction. 2|il of this reaction was then 
incubated with 5|ig of purified GST, GST-Racl, GST-RhoA or GST-Cdc42 in 500^1 of 
complex formation assay buffer (20mM Tris pH 7.5; lOOmM NaCl; 2.0mM EDTA; 
0.5%Triton X 100) with 25|il of glutathione sepharose beads (Amersham Pharmacia) for 2hrs 
at 4°C. The beads were spun down and washed five times with the same buffer. The beads 
were then boiled in SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE, 
followed by western transfer and autoradiography. 
Lipid Overlay Blot 
The lipid overlay was carried out as described earlier (25). The phospholipid array 
(Echelon Inc.) was incubated overnight with lOnM purified GST tagged PH domain of 
P-Rex2. The blot was washed and incubated with an anti-GST antibody (Molecular Probes). 
The blot was washed extensively and developed using an HRP-tagged anti-rabbit secondary 
antibody, and a chemiluminescent system (Pierce). 
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Analysis of GJ3y binding 
Binding assays were done using a modified protocol described elsewhere (15). 
G(3iY2 subunits purified from Sf9 cells were spotted onto a nitrocellulose membrane and 
incubated with 5^1 of the DH or PH domain of P-Rex2 that had been labeled with [35]S Met 
as before, in 5ml of buffer (20mM Tris.Cl pH 7.5, lOOmM NaCl, ImM EDTA, 0.01% 
Lubrol) overnight at 4°C. The blots were washed five times with the same buffer, dried and 
then developed by autoradiography. The bands were quantified by densitometry and the 
amount of bound protein was expressed as a fraction of the total protein used in the overlay. 
Guanine Nucleotide Exchange Assay 
The in vitro GEF assay was performed on a Mithras LB 940 (Berthold Technologies) 
fluorescence spectrophotometer by modifying a basic protocol described elsewhere (26). 
2jiM of purified GST-tagged Rho family G protein was incubated with lOOnM of purified 
GST-tagged P-Rex2 and 400nM Mant-GDP (Molecular Probes) in 50|il of exchange buffer 
(20mM Tris, pH 7.5, 50mM NaCl, lOmM MgCl2, ImM DTT, 50|ig/^l BSA and 10% 
glycerol). Excitation and emission wavelengths were 355nm and 460nm, respectively. GEF 
assays with lipids and G(3y subunits were carried out as described earlier (17). Mixed 
phospholipid liposomes (PtdCho, PtdS and Ptdlns, final assay concentration 200pM each), 
were sonicated in lipid buffer (20mM HEPES/NaOH pH 7.5, lOOmM NaCl, ImM EGTA) 
with or without Ptdlns(3,4,5)P^ (final assay concentration lO^iM). 
Cell Culture and Membrane Ruffling Assay 
NIH 3T3 mouse fibroblast cells were plated on poly-lysine coated cover slips and 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf 
serum. The cells were transfected with expression plasmids encoding V5-tagged P-Rex2 or 
GFP using Effectene (Qiagen), according to the manufacturers instructions. The cells were 
starved 6 h post transfection in DMEM containing 0.5% calf sera, for 12-14 h. The cells were 
pre-incubated or not with lOOnM wortmannin, and then stimulated with lOng/ml of PDGF 
for 10min. The cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.5% 
Triton X-100, and then labeled with an anti-V5 or anti-GFP antibody to detect protein and 
Rhodamine phalloidin to detect filamentous actin as described earlier (24). Images were 
captured with a Spot RT digital camera (Roche Diagnostics) on a Nikon E800 microscope. 
RESULTS 
Cloning and expression ofP-Rex2 
BLAST searches for sequences similar to IP4Ps revealed the presence of two partial 
overlapping EST clones (AK024079 and AK023049). Human P-Rex2 was PCR amplified 
using oligonucleotides based on these sequences, and additional 5' sequence was obtained 
using 5'RACE. P-Rex2 cDNA is 4903 bp long with an open reading frame (ORF) of 4821 
bp. The putative start ATG is preceded by a Kozak consensus sequence. However, as in the 
case of its homologue P-Rexl, the 5' end of this gene is extremely GC-rich and there is no in 
frame stop codon 5' of the putative start ATG leaving the possibility of additional 5' coding 
sequence. (17). 
Amino acid sequence analysis of P-Rex2 shows that it is composed of 1606 amino 
acids, predicting a protein of 182,679 Da. This is similar to the 185 kDa molecular weight of 
endogenous P-Rexl purified from neutrophils, and the predicted size of P-Rexl based on its 
ORF (17). Sequence comparison between P-Rexl and P-Rex2 show that they share 55% 
identity at the amino acid level (Fig. 1A). The domain architecture of P-Rex2 is the same as 
that of P-Rexl and is composed of an N-terminal DH/PH domain, followed by two DEP 
domains and two PDZ domains, and a C-terminal IP4P-like domain, consisting of 324 amino 
acids (Fig. IB, [17]). 
Northern blot analysis of P-Rex2 expression shows a -12 kb message in skeletal 
muscle and placenta, consistent with the message having long untranslated regions or 
additional coding sequence (Fig. 2). This expression pattern differs from that of P-Rexl, 
which is mainly expressed in peripheral blood leukocytes and brain (17). Analysis of the 
human genomic sequence shows that P-Rex2 is located on chromosome 8ql3.1, while 
P-Rexl is on chromosome 20ql3.13 (17). The gene for P-Rex2 is uncommonly large, with 
an ORF derived from 40 exons spanning ~290kb of DNA. It therefore falls into a rare 
category of genes, as less than 2% of mammalian genes are more than lOOkb in length (27). 
Analysis of the IP4P-like domain ofP-Rex2 
IP4Ps are Mg++ independent enzymes that catalyze the hydrolysis of the 4-position 
phosphate of PtdIns(3,4)P2. They are characterized by the presence of an active site motif 
CKSAKDRT, where the cysteine is the reactive nucleophile required for catalysis (20,21). 
Comparison of the IP4P-like domain of P-Rex2 with the IP4P family of proteins, shows that 
it shares 28% identity and 44% homology with human IP4P Type I. However, the critical 
amino acids within the putative phosphatase P-loop CX5R consensus active site sequence of 
P-Rex2 and P-Rexl have diverged from the consensus sequence of IP4Ps (Fig. 3). The 
conserved threonine residue that follows the CX5R active site motif of LP4Ps is also not 
maintained in P-Rex2. Phosphatase assays with GST-fusions of full length, and the 
phosphatase domain alone of P-Rex2, showed no detectable hydrolysis of Ins(l,3,4)P3, 
Ins(l,3,4,5)P4, PtdIns(3)P, PtdIns(4)P, PtdIns(3,4)P2, PtdIns(3,5)P2, PtdIns(4,5)P2, 
phosphatidic acid or para-nitrophenolphosphate as substrates (data not shown). 
Analysis of the GEF domain ofP-Rex2 
Racl, RhoA and Cdc42 are prototypical members of the Rho family G proteins (1). 
The DH/PH domain of Dbl family GEFs vary in their degree of specificity in binding to Rho 
family G proteins (6). To determine the substrate specificity of P-Rex2, the DH/PH domain 
of P-Rex2 was used in an in vitro substrate binding assay. As a positive control, we used the 
DH/PH domain of Dbl, which has the ability to bind to Rho, Rac and Cdc42 (28). As shown 
in Fig.4, the DH/PH domain of P-Rex2 was able to bind only to Racl, suggesting that it is a 
Rac specific GEF. 
Analysis of the binding properties of the PH domain ofP-Rex2 
The PH domain is thought to be a lipid binding as well as a protein-protein interaction 
module (8). To determine the lipid preference of the PH domain of P-Rex2, the PH domain 
was expressed and purified from Sf9 cells and incubated with a phospholipid overlay blot. As 
shown in Fig.5A, the PH domain of P-Rex2 preferentially bound PtdIns(3,5)P2, followed by 
PtdIns(3,4,5)Ps. It also bound with weaker affinity to Ptdlns(3,4)?2, PtdIns(4)P, and 
PtdIns(5)P. 
The GEF activity of P-Rexl was reported to be stimulated by G (By subunits, however 
the domain responsible for this interaction was not identified (17). The PH domains of some 
proteins have been shown to interact with G (By subunits (15,16). To determine whether the 
PH domain of P-Rex2 can interact with G(By subunits, the PH and DH (negative control) 
domains of P-Rex2 were labeled with [351S Met and incubated with purified G (By subunits that 
were immobilized on a nitrocellulose membrane. As shown in Fig. 5B, the PH domain could 
interact with G(3y subunits in a dose dependent manner while the DH domain of P-Rex2 
showed minimal interaction with G(By subunits. 
Analysis of the in vitro GEF activity of P-Rex2 
Lipid binding by the PH domain of Rho family GEFs has been shown to modulate the 
activity of many GEFs (11,12,13,14). The GEF activity of P-Rexl on Rac is stimulated by 
PtdIns(3,4,5)Pg and G (By subunits (17). To determine whether the GEF activity of P-Rex2 was 
also regulated, nucleotide exchange assays were performed using full-length P-Rex2 purified 
from Sf9 cells. As shown in Fig.6A and B, P-Rex2 exchange activity on Racl was stimulated 
with increasing concentrations of PtdIns(3,4,5)P^ or G (By subunits. Furthermore, as in the 
case of P-Rexl, presence of these activators was an absolute necessity for the activity of 
P-Rex2 (Table 1). Surprisingly, despite the fact that the PH domain bound with highest 
affinity to PtdIns(3,5)Pz, P-Rex2 could not be activated by this lipid (data not shown). 
P-Rex2 retains its substrate selectivity and does not catalyze exchange on RhoA and Cdc42 
even in the presence of PtdIns(3,4,5)P3 or G [By subunits (data not shown). Simultaneous 
addition of PtdIns(3,4,5)P3 and G(3y subunits showed no enhancement in activity of P-Rex2 
when compared to the maximal activation achieved by either factor alone. Therefore unlike 
P-Rexl, P-Rex2 is not activated synergistically by PtdIns(3,4,5)Ps and G(3y subunits (Table 
1). 
In vivo activity and regulation ofP-Rex2 
Formation of membrane ruffles is the hallmark of Rac activation in vivo in NIH 3T3 
cells. Activation of Cdc42 causes the formation of filopodia and RhoA causes stress fiber 
formation (2). To determine if P-Rex2 could activate a Rho family G protein in vivo, NIH 
3T3 cells were transfected with P-Rex2 or GFP (negative control) expression constructs and 
the formation of actin-based structures was assessed. As shown in Fig.7A and B, no changes 
in actin-based structures were observed in P-Rex2 transfected cells in the absence of 
stimulation. However upon PDGF stimulation, cells expressing P-Rex2 showed enhanced 
formation of membrane ruffles. Pre-incubation of the cells with wortmannin, an inhibitor of 
PI3K, led to a decrease in the formation of membrane ruffles. This is consistent with PI3K-
generated lipid second messengers being able to regulate P-Rex2 GEF activity in vivo. 
P-Rex2 is mainly cytosolic, and no major changes in localization of the protein was observed 
upon PDGF stimulation. In addition, the ability of P-Rex2 to activate Rac in vivo is not 
influenced by the phosphatase domain, as deletion constructs lacking the phosphatase domain 
did not differ in their ability to form membrane ruffles in stimulated or unstimulated cells 
(data not shown). 
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DISCUSSION 
P-Rexl is a Rac specific GEF that plays a key role in stimulating neutrophil oxidative 
burst (17). Here we describe the characterization of P-Rex2 a homologue of P-Rexl. P-Rexl 
and P-Rex2 share 55% sequence identity at the amino acid level and share the same domain 
architecture with an N-terminal DH/PH domain followed by two DEP, two PDZ domains and 
a C-terminal IP4P-like domain ([17], Fig. 1A and B). DEP domains are domains of unknown 
function that have been identified in a large number of proteins involved in the regulation of 
G protein signaling (29,30). PDZ domains are involved in protein-protein interactions and 
can bind to the C-terminal end of several membrane proteins (31). They have also been 
shown to bind to internal domains of proteins via a (Winger structure (32). Intriguingly, the 
crystal structure of DEP domains shows that they have a (Winger structure, which is thought 
to serve as a docking site for other proteins (29). The tandem arrangement of the paired DEP 
and PDZ domains in both P-Rexl and P-Rex2 suggests that they may be involved in an intra 
molecular interaction. Experiments evaluating the role of these domains in P-Rex2 are 
currently underway. 
IP4Ps have been shown to be involved in a wide variety of processes including 
platelet aggregation, neuronal development, regulation of megakaryocyte differentiation and 
neutrophil oxidative burst (33,34,35,22). The IP4P-like domain of P-Rex2 is about 320 
amino acids long, and is 28% identical to human IP4P type I. This domain contains a P-loop 
CX5R active site motif, that is a signature motif found in the active site of a wide variety of 
metal ion-independent phosphatases, including inositol phosphatases, serine/threonine 
phosphatases and dual specificity protein phosphatases (36,37). The members of the IP4P 
family of enzymes share an active site consensus sequence of CKSAKDRT that is 
evolutionarily conserved from bacteria to mammals. Changes in the conserved C, R or D 
residues within the IP4P active site consensus sequence lead to a loss in its activity ([20,38], 
unpublished results). Despite the overall homology between the IP4P-like domain of P-Rex2 
and 1P4P, the active site consensus sequence for IP4P has not been maintained in P-Rex2 or 
P-Rexl (Fig.3). Moreover, the active site motifs of P-Rexl and P-Rex2 differ from each 
other. These differences suggest that P-Rex proteins may hydrolyze unique and separate 
substrate categories. In support of this idea, no phosphatase activity could be detected for full 
length or phosphatase domain alone form of P-Rex2 when Ins(l,3,4)P3, Ins(l,3,4,5)P^, 
phosphatidic acid, PtdIns(3)P, PtdIns(4)P, PtdIns(3,4)P2, PtdIns(3,5)P2 ,PtdIns(4,5)Pz or 
para-nitrophenolphosphate were used as substrates. P-Rexl also showed no hydrolysis of 
PtdIns(3,4)Pi, PtdIns(3,4,5)P; or para-nitrophenolphosphate (17). Although traditional 
IP4Ps are not known to require accessory proteins or modifications for its activity, given the 
conditional nature of the GEF activity of P-Rex2, it is possible that its phosphatase activity 
also requires other regulatory inputs. 
Based on in vitro binding studies and nucleotide exchange assays, P-Rex2 is specific 
for Rac. Moreover, as was previously reported in P-Rexl, P-Rex2 exchange activity required 
the presence of either PtdIns(3,4,5)P3 or G (By subunits. However, P-Rex2 unlike P-Rexl was 
not activated synergistically by PtdIns(3,4,5)Pg and G(3y subunits, as no increase in maximal 
activity was observed in the presence of both effectors (17). In addition, P-Rex2 can enhance 
the formation of membrane ruffles in PDGF stimulated NIH 3T3 cells, which is a hallmark of 
Rac activation in vivo. Pre-incubation of the cells with wortmannin abolishes this effect. This 
is consistent with the ability of PI3K second messengers being able to activate P-Rex2 in 
vivo. Although P-Rexl was reported to catalyze exchange on both Racl and Cdc42 in vitro 
(17), our own binding analysis with the DH/PH domain of P-Rexl shows that it is capable of 
binding only Racl and not Cdc42 in vitro (Unpublished results). However, this is consistent 
with the in vivo activity reported for P-Rexl which shows that it is a Rac specific GEF (17). 
Although P-Rexl has been shown to be activated by both PtdIns(3,4,5)P3 and GfBy 
subunits, the domain/s responsible for this interaction have not been identified (17). PH 
domains are lipid binding modules found in a large number of proteins (8). The PH domains 
of some proteins are also involved in protein-protein interactions including binding to G(3y 
subunits (15,16). As the GEF activity of P-Rex2 was stimulated by Ptdlns(3,4,5)P3 and 
GPy subunits, the PH domain of P-Rex2 was evaluated for its ability to bind to these 
effectors. The PH domain of P-Rex2 was able to interact with both Ptdlns(3,4,5)P3 and 
GPy subunits (Fig. 5A and B). However, the PH domain could also bind to other inositol 
lipids including PtdIns(3,5)Pi, a second messenger generated during osmotic stress conditions 
within mammalian and yeast cells (39). Surprisingly, the GEF activity of P-Rex2 was not 
stimulated by PtdIns(3,5)Pz, suggesting that this lipid could potentially compete for 
PtdIns(3,4,5)P3 binding by the PH domain and thereby serve as a negative regulator of 
P-Rex2. 
P-Rexl has been shown to play a major role in neutrophil oxidative burst. Antisense 
oligonucleotides directed against P-Rexl were able to reduce the formation of reactive 
oxygen species by 40-45% in response to C5a in a neutrophil-like cell line (17). Rac2, the 
major isoform of Rac expressed in neutrophils, is an essential and required component of the 
NADPH oxidase complex in leukocytes (40). Rac is able to bind directly to the N-terminus 
of p67phox, an essential component of the NADPH complex, via its switch I domain (41). 
Rac2"A neutrophils had significantly reduced superoxide production in response to various 
stimuli (40). Human P-Rex2 is a Rac specific GEF that is expressed in skeletal muscle tissue 
and in the placenta. A non-phagocytic oxidative burst complex has been identified in skeletal 
muscle cells, however the role of this oxidase complex in these cells is not clear (42). 
Reactive oxygen species produced by non-phagocytic oxidase complexes have been shown 
to influence cell signaling, gene expression, cell proliferation, and contractile function 
(43,44). P-Rex2 may serve to activate this complex in skeletal muscle cells by activating 
Rac. Additional experiments will be needed to evaluate the in vivo role of P-Rex2 and its 
mechanism of activation. 
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FOOTNOTES 
The nucleotide sequence for human P-Rex2 gene has been deposited in the GenBank 
database under GenBank Accession Number AY508996. 
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ABBREVIATIONS 
IP4P, inositol polyphosphate 4-phosphatase; PI3K, phosphoinositide 3-kinase; 
PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-trisphosphate; PtdIns(3,5)P2, phosphatidylinositol 
3,5-bisphosphate; PtdIns(3,4)P2, phosphatidylinositol 3,4-bisphosphate; GEF, guanine 
nucleotide exchange factor; Dbl, diffuse B-cell lymphoma; DH, Dbl homology; PH, 
pleckstrin homology; GFP, green fluorescent protein; mant-GDP, N-methylantranioyl-GDP; 
PDGF, Platelet derived growth factor; FITC, fluorescein isothiocyanate; RACE, rapid 
amplification of cDNA ends; GST, glutathione S-transferase; HRP, horse radish peroxidase; 
PBS, phosphate buffered saline. 
FIGURE LEGENDS 
FIG. 1. Structure of P-Rex2. (A) Amino acid sequence alignment between P-Rex2 (top 
sequence) and P-Rexl (bottom sequence). The putative phosphatase active site is indicated 
with an overhead line. (B) Schematic showing domain architecture of P-Rex2. 
FIG. 2. Northern blot analysis of P-Rex2. Multi-tissue northern blot (CLONTECH), 
analysis of human P-Rex2 shows a single transcript of ~12kb that is mainly expressed in 
skeletal muscle tissue and in the placenta. 
FIG. 3. Sequence comparison of the IP4P active sites with that of P-Rexl and P-Rex2 
The CX5R putative active site of P-Rex2 and P-Rexl is compared with other IP4P family 
members (Human IP4P Type I and II, C. elegans IP4P, Shigella IpgD, and Salmonella 
SopB). The conserved cysteine and arginine are boxed and the (*) indicates the position of 
the conserved threonine in IP4Ps. 
FIG. 4. Complex Formation Assay. The DH/PH domains of P-Rex2 and Dbl (positive 
control) were labeled with [35]S Met and analyzed for their ability to bind to GST (negative 
control), GST-tagged Racl, RhoA or Cdc42 in a pull-down assay. The amount of bound 
protein was determined by western blotting and autoradiography. 
FIG. 5. Analysis of the PH domain of P-Rex2. (A) PH domain lipid overlay blot. The 
phospholipid binding property of the PH domain of P-Rex2 was assessed by incubating 
lOnM purified GST-tagged PH domain with a phospholipid array (Echelon). The blot was 
then developed using an anti-GST antibody. (B) Binding of G(3y subunits by P-Rex2. The 
DH and PH domains of P-Rex2 were labeled with [35]S Met and tested for their ability to bind 
to GP1Y2 subunits that had been immobilized on a nitrocellulose membrane (inset). The bands 
were identified by autoradiography and quantified by densitometry. The amount of bound PH 
domain (black bars) and DH domain (white bars) to the indicated amounts of GP1Y2 subunits 
was expressed as a fraction of the total protein used in the overlay. Data shown is 
representative of two independent experiments. 
FIG. 6. Regulation of the in vitro GEF activity of P-Rex2. In vitro GEF activity of P-Rex2 
was monitored by the increase in fluorescence associated with the binding of Mant-GDP by 
Rac. (A) Effects of PtdIns(3,4,5)P3 on the in vitro GEF activity of P-Rex2. The effect of the 
addition of mixed phospholipid liposomes containing 0|iM (open circles), 2.5|iM (filled 
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circles), 5pM (filled triangles), or 10|iM(open squares) PtdIns(3,4,5)P3 on the GEF activity 
of P-Rex2 on Racl. (B) Effect of G(3y on the in vitro GEF activity of P-Rex2. The effect of 
addition of 0|iM (filled circles), 0.4|iM (filled squares), 0.8|iM (filled triangles) and 1.6|iM 
(open squares) GjBy subunits on the GEF activity of P-Rex2 on Racl. Racl alone without 
P-Rex2 is shown in open circles. 
FIG. 7. P-Rex2 is a Rac specific GEF in vivo. (A) Fluorescence micrographs of GFP and 
P-Rex2 transfected cells. NIH 3T3 cells transiently expressing GFP (control) or V5-tagged 
P-Rex2 were serum starved and then subsequently stimulated with 10ng/ml PDGF (a,b,e and 
f). Panels c and d show P-Rex2 expressing cells without stimulation. Cells expressing GFP 
(a) or P-Rex2 (c and e) were detected by immunofluorescence staining. The cells were 
double labeled with Rhodamine-Phalloidin (b,d,f) to detect actin. (B) Quantification of 
fluorescence microscopy data. Fifty GFP or P-Rex2 transfected cells from two cover slips 
were assessed for the formation of membrane ruffles under the following conditions: (1) GFP 
without PDGF, (2) GFP with PDGF, (3) P-Rex2 without PDGF, (4) P-Rex2 with PDGF, (5) 
P-Rex2 with PDGF and lOOnM wortmannin. Data shown is the average of two independent 
experiments. 
50 
Table 1. Initial rates of guanine nucleotide exchange reactions catalyzed by P-Rex2 on Racl. 
Rate (Rel. fluorescence Fold 
units/sec) xlO"3 Activation 
Racl 
Racl + P-Rex2 
Racl + P-Rex2 + 0.4 G|3y 
Racl + P-Rex2 + 5piM PtdIns(3,4,5)P3 
Racl + P-Rex2 + 5|iiM PtdIns(3,4,5)P3 + 
0.4|iiM Gpy 
0.2 
0.2 
2.1 
2.3 
2.2 
1 
10.5 
11.5 
11.5 
The initial rates of guanine nucleotide exchange for 2|iM Racl catalyzed by lOOnM P-Rex2 
were determined by linear regression analysis of approximately the first 60 seconds of each 
reaction. The fold activation reflects the ratio of the initial rate for the P-Rex2 containing 
reaction to the intrinsic rate of exchange for Racl. Data shown is representative of two 
independent experiments. 
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P-REX2B, AN ALTERNATE SPLICE VARIANT OF P-REX2: 
EVIDENCE FOR THE DEP DOMAINS OF P-REX2 AS NOVEL LIPID-
BINDING DOMAINS. 
A paper submitted to Biochemical Journal 
Raji E. Joseph1, and F. Anderson Norris* 
SUMMARY 
P-Rexl and P-Rex2A are unusual guanine nucleotide exchange factors (GEFs) for 
Rac with an inositol polyphosphatase 4-phosphatase (IP4P)-like domain. We have cloned 
P-Rex2B, a shorter alternate splice variant of P-Rex2A, which retains the N-terminal DH/PH 
domain, two DEP domains and two PDZ domains, but lacks the C-terminal domain with 
IP4P homology. Genomic sequence analysis of human P-Rex2 gene shows that it has a 
complex architecture with 41 exons that can be utilized as coding sequence. P-Rex2B shares 
with P-Rexl and P-Rex2A the unusual requirement of phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) or G (By subunits for its GEF activity on Rac in vitro. P-Rex2B 
also stimulates the formation of membrane ruffles in PDGF stimulated NIH 3T3 cells, 
indicating that it can also function as a Rac specific GEF in vivo. The activity of P-Rex2B did 
not differ from that of P-Rex2A, suggesting that the phosphatase domain does not influence 
its ability to activate Rac in vitro or the ability of Rac to form membrane ruffles in vivo. In 
addition, we show that the DEP domains of P-Rex2 are novel lipid binding domains that can 
specifically bind to phosphorylated inositol lipids. Thus, the P-Rex family of GEFs appears 
to use a unique mechanism to couple the production of phosphoinositides to Rac activation. 
'Primary Researcher and author. 
* Author for correspondence. 
INTRODUCTION 
Rho family G proteins act as molecular switches that cycle between an active GTP 
bound state and an inactive GDP bound state. They are activated by guanine nucleotide 
exchange factors (GEFs), which catalyze the exchange of GDP for GTP. The Rho family G 
proteins consist of about 18 members to date, of which Rac, Rho and Cdc42 are the most 
widely studied and well characterized. These G proteins are involved in a wide variety of 
functions, including actin cytoskeletal rearrangements, cell migration, gene expression, cell 
proliferation and the neutrophil oxidative burst [1,2,3,4]. 
The Dbl family of GEFs catalyzes exchange on the Rho family G proteins. The Dbl 
family consists of about 80 mammalian family members, some of which are very specific, 
causing exchange on only one small G protein, while others are broadly specific and 
stimulate exchange on several G proteins [5]. They are characterized by the presence of a 
catalytic Dbl homology (DH) domain of -200 amino acids which is invariably followed by a 
pleckstrin homology (PH) domain [5,6]. PH domains consist of -100 amino acids and are 
lipid binding modules found in a wide variety of signaling proteins [7]. They are thought to 
mediate membrane localization of some GEFs, while in others, to modulate the activity of the 
DH domain [8,9,10], 
P-Rexl and P-Rex2 are Rac specific GEFs that are unusual in that their GEF activity 
is conditional on the presence of either phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3) or G (By subunits [11, Raji E. Joseph and Frank A. Norris, unpublished data]. 
Human P-Rexl is mainly expressed in neutrophils, where it plays a key role in stimulating 
the neutrophil oxidative burst [11]. This expression pattern differs from that of human 
P-Rex2, which is expressed in skeletal muscles and placenta [Raji E. Joseph and Frank A. 
Norris, unpublished data]. They share 55% identity at the amino acid level and have a 
common but complex domain architecture with an N-terminal DH/PH domain, followed by 
two DEP domains, two PDZ domains and a C-terminal inositol polyphosphate 4-phosphatase 
(IP4P)-like domain. PDZ domains are protein-protein interaction modules that have been 
shown to bind the C-terminal ends of membrane proteins or internal domains of proteins 
containing a (3-hairpin structure [12,13]. IP4Ps are enzymes that catalyze the hydrolysis of 
the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)Pz) [14]. IP4Ps 
have been shown to be involved in a wide variety of processes including platelet aggregation, 
neuronal development, regulation of megakaryocyte differentiation and the neutrophil 
oxidative burst [15,16,17,18]. 
DEP domains (named after Dishevelled, Egl-10 and Pleckstrin) are evolutionary 
conserved from bacteria to mammals [19]. Although they have been found in a large number 
of proteins involved in the regulation of G protein signaling, their in vivo function remains 
largely unknown [20]. The structures of the DEP domains of Dishevelled and Epac2 showed 
that they have a unique fold that is not shared by other proteins in the structural database [19, 
21]. The core is formed by three a-helices (HI, H2 and H3), a |3-hairpin 'arm' between HI 
and H2, and a two short ^-strands following H3. The tertiary structure is stabilized by 
extensive hydrophobic interactions between the three helices. The two most notable features 
of this structure are the ^-hairpin 'arm' and a cluster of basic residues located on the surface 
of this domain. The (B-hairpin 'arm' has a strong electric dipole associated with it, a feature 
that is common in protein-protein docking interfaces [19]. The cluster of basic residues on 
the surface of Dishevelled has been speculated to interact with negatively charged membrane 
lipids [19]. The DEP domains of several other proteins including Epac, RGS9 and EGL-10, 
have been shown to mediate membrane association [22,23,24]. However, the in vivo ligand/s 
for this domain, protein and/or lipid, has not been established. Moreover, as the P-hairpin 
'arm' and the basic cluster are located on opposite surfaces of the domain, it is feasible that 
the DEP domain may interact simultaneously with both proteins and lipids [19]. 
Although P-Rexl and P-Rex2 share significant similarity with IP4Ps, phosphatase 
function could not be ascertained for either protein [11, Raji E. Joseph and Frank A. Norris, 
unpublished data]. A naturally occurring form of P-Rex that lacks this domain would 
facilitate the assessment of the function of the phosphatase-like domain. In this report, we 
describe the cloning and characterization of P-Rex2B, a spliceoform of P-Rex2 that lacks the 
phosphatase-like domain. Genomic sequence analysis of P-Rex2 revealed a complex gene 
structure with 41 exons and unusually large introns. Biochemical characterization shows that 
P-Rex2B is a Rac specific GEF in vitro and in vivo, and its GEF activity is conditional on the 
presence of either PtdIns(3,4,5)Pg or Gpy subunits. Moreover, we identify the DEP domains 
of P-Rex2 as novel lipid-binding domains, capable of specifically interacting with 
phosphorylated inositol lipids. 
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MATERIALS AND METHODS: 
Materials 
Wild type bacterial expression construct for RhoA was created by PGR amplification 
and cloned into the Smal/NotI sites of pGEX 4T-1 (Amersham Pharmacia Biotech). Stearyl-
arachidonyl-PtdIns(3,4,5)P3 was obtained from Maytreya Inc. Phosphatidylcholine (PtdCho), 
phosphatidylinositol (Ptdlns), phosphatidylserine (PtdS), were obtained from Avanti Polar 
Lipids Inc. The FITC-anti-mouse secondary antibody and Rhodamine-Phalloidin were from 
Molecular Probes. The anti-V5 mouse monoclonal antibody was from Invitrogen. 
Cloning of human P-Rex2B 
Blast searches for sequences similar to P-Rex2 revealed the presence of a partial EST 
clone (AK023049). A 1196 bp fragment encompassing the 3' end of the gene was amplified 
from a Human Mammary Gland Marathon-Ready™ cDNA library (CLONTECH) by PGR 
using gene specific oligonucleotides 5 '-GGCAGCTATGGCTTTGGGCTAG-3 ' (sense) and 
5'-CTAGGAAGGGCTGTGTACTGTG-3 ' (antisense). Upstream sequence was obtained by 
nested 5'RACE reactions using flanking library specific oligonucleotides and the gene 
specific oligonucleotides 5'-GCGCCGCGCTGCGCACCGCCG-3' (sense) and 
5'-CTGGAAGCCAAGTCCATCAGC-3' (antisense). The cDNA for P-Rex2B is 3024 bp, 
and was cloned into pcDNA3.1D/V5-His-TOPO vector (Invitrogen) for mammalian 
expression and into the Ndel/NotI sites of the pAcGHLT-A vector (BD Biosciences 
Pharmingen) for expression in Sf9 cells by PGR. The DEP1DEP2 domains (amino acid 
residues 387 to 567) were cloned into the Smal/NotI sites of pGEX4T-l vector for bacterial 
expression by PGR. 
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Northern Blotting 
Human multi-tissue northern blots (CLONTECH) were probed with [y-32P] ATP 5' 
end labeled P-Rex2B specific oligonucleotide 
(5 ' -GACAGGGGCCCTCTCTGCTAAGAGCATTTCTTGAGAAGGAAGGTC-3 ' ) using 
Express Hyb (CLONTECH) according to the manufacturers' instructions. 
Expression and purification of proteins 
GST and GST-tagged Racl, RhoA, Cdc42 and DEP1DEP2 domains of P-Rex2 were 
expressed and purified from Escherichia coli as described elsewhere [25]. GST-tagged 
P-Rex2B was expressed and purified from Sf9 cells as described earlier [11]. 
Lipid Overlay Blot 
The lipid overlay was carried out as previously described [26]. The lipid blot was 
incubated overnight at 4°C with lOnM purified GST-tagged P-Rex2B or GST-tagged 
DEP1DEP2 domains of P-Rex2. The blot was washed and incubated with an anti-GST 
antibody (Molecular Probes). The blot was washed extensively and developed using an HRP-
tagged anti-rabbit secondary antibody, and a chemiluminescent system (Pierce). 
Guanine Nucleotide Exchange Assay 
The in vitro GEF assay was performed on a Mithras LB 940 (Berthold Technologies) 
fluorescence spectrophotometer by modifying a basic protocol described elsewhere [27]. 
2|iM of purified GST-tagged Rho family G protein was incubated at room temperature with 
lOOnM of purified GST-tagged P-Rex2B and 400nM Mant-GDP in 50(J,1 of exchange buffer 
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(20mM Tris, pH 7.5, 50mM NaCl, lOmM MgCl2, ImM DTT, 50^ig/^il BSA and 10% 
glycerol). Excitation and emission wavelengths were 355nm and 460nm, respectively. GEF 
assays with lipids and G(3y subunits were carried out as described earlier [11]. Mixed 
phospholipid liposomes (PtdCho, PtdS and Ptdlns, final assay concentration 200|iM each), 
were sonicated in lipid buffer (20mM HEPES/NaOH pH 7.5, lOOmM NaCl, ImM EGTA) 
with or without PtdIns(3,4,5)P3 (final assay concentration 5|oM). 
Cell Culture and Membrane Ruffling Assay 
NIH 3T3 mouse fibroblast cells were plated on poly-lysine coated cover slips and 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf 
serum. The cells were transfected with expression plasmids encoding V5-tagged P-Rex2B or 
GFP using Effectene (Qiagen), according to the manufacturers instructions. The cells were 
starved 6 h post transfection in DMEM supplemented with 0.5% calf serum, for 12-14 h. The 
cells were then stimulated with lOng/ml of PDGF for 10min. The cells were fixed with 4% 
paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100, and then labeled with an 
anti-V5 or anti-GFP antibody to detect protein and Rhodamine phalloidin to detect 
filamentous actin as described earlier [28]. Images were captured with a Spot RT digital 
camera (Roche Diagnostics) on a Nikon E800 microscope. 
RESULTS AND DISCUSSION 
Cloning, gene structure and expression ofP-Rex2B 
P-Rexl and P-Rex2 (hereafter referred to as P-Rex2A) have a C-terminal IP4P 
phosphatase-like domain. However, in vitro phosphatase assays with both P-Rexl and 
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P-Rex2A have failed to detect any activity for either protein [11, Raji E. Joseph and Frank A. 
Norris, unpublished data]. BLAST searches for proteins similar to P-Rex2A revealed the 
presence of an alternate splice variant (EST clone AK023049). Interestingly, this spliceoform 
designated P-Rex2B, lacked the phosphatase-like domain. Oligonucleotides were designed 
based on this sequence and a 3024 bp PGR product encoding P-Rex2B was obtained. 
P-Rex2B consists of 979 amino acids, predicting a protein of 112,116 Da [Fig. 1A]. This is 
considerably smaller than P-Rex2A, which has a predicted mass of 182,679 Da. The domain 
architecture of P-Rex2B consists of an N-terminal DH/PH domain, two DEP domains, two 
PDZ domains and a novel C-terminal domain, which is 74 amino acids long [Fig. IB]. The 
existence of two forms of P-Rex2 with and without the phosphatase-like domain, make this 
naturally occurring splice variant an invaluable tool to evaluate the role of the phosphatase-
like domain. 
Analysis of the human genomic database revealed that the gene encoding P-Rex2 is 
located on chromosome 8ql3.1. The gene for human P-Rex2 is unusually large and is spread 
across > 290 kb of DNA. This gene contains 41 exons that can be utilized as coding sequence 
[Table 1]. P-Rex2A is formed by using exons 1 through 41, excluding exon 24. P-Rex2B is 
formed using exons 1 through 24 (Fig. 1C). While the size of the exons range from 42 bp 
(exon 32) to 225 bp (exon 24), the size of the introns varies more dramatically from 160 bp 
(intron 16) to 65,310 bp (intron 1) [Table 1]. Introns 1 (65,310 bp), 36 (34,284 bp), and 38 
(25,091 bp) are unusually large as less than 2% of mammalian introns are over 10,000 bp 
long [29]. 
Northern blot analysis using a probe derived from the sequence unique to the 
C-terminus of human P-Rex2B, shows the presence of three major transcripts [Fig. 2], A 6 kb 
transcript is expressed in all the tissues tested. A 5 kb transcript is expressed in skeletal 
muscle tissue, while an 8 kb transcript is expressed in skeletal muscles and heart. The 
complexity of this expression pattern suggests that there are still other additional splice 
variants. Interestingly, P-Rex2B is poorly expressed in peripheral blood leukocytes [Fig. 2], 
the tissue where P-Rexl is mainly expressed [11]. The expression pattern of P-Rex2B also 
varies from that of P-Rex2A, whose single 12 kb transcript is mainly expressed in skeletal 
muscles and placenta [Raji E. Joseph and Frank A. Norris, unpublished data]. 
In vitro GEF activity of P-Rex2B 
The GEF activity of P-Rex2A on Rac is conditional on the presence of either 
PtdIns(3,4,5)P3 or G (By subunits [Raji E. Joseph and Frank A. Norris, unpublished data]. To 
determine the exchange properties of P-Rex2B, its GEF activity was tested using purified 
full-length recombinant protein. As shown in Fig.3 and Table 2, the GEF activity of P-Rex2B 
was also conditional on the presence of PtdIns(3,4,5)Ps or G (By subunits. Moreover, P-Rex2B 
is not activated synergistically by both PtdIns(3,4,5)Ps or G(By subunits, a property that is 
similar to that of P-Rex2A. P-Rex2B is specific for Racl, and did not catalyze exchange on 
either Rho A or Cdc42 [data not shown]. These exchange properties of P-Rex2B were the 
same as what has been previously observed for P-Rex2A. Both proteins stimulated an -10 
fold increase in initial rate of exchange over the intrinsic rate of exchange for Racl, in the 
presence of either 5|oM PtdIns(3,4,5)P3 or 0.4|iM G (By subunits. This indicates that the 
phosphatase-like domain does not influence the specificity or the kinetics of the exchange 
reactions in vitro. Thus, the P-Rex family of GEFs are Rac specific and are exquisitely 
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regulated by both PtdIns(3,4,5)P3 or G (By subunits [11, Raji E. Joseph and Frank A. Norris, 
unpublished data]. 
In vivo GEF activity ofP-Rex2B 
Activation of Rac in vivo leads to the formation of membrane ruffles, while activation 
of Rho or Cdc42 leads to the formation of stress fibers and filopodia respectively [2]. To 
determine whether P-Rex2B can activate a Rho family G protein in vivo, NIH 3T3 cells were 
transfected with expression constructs for P-Rex2B or GFP, and were assessed for the 
formation of actin based structures. As shown in Fig. 4A and B, in the absence of 
stimulation, P-Rex2B overexpression did not show any changes in actin-based structures 
relative to GFP control. However, upon stimulation with PDGF, 86% of P-Rex2B transfected 
cells had membrane ruffles compared to 46% of GFP transfected cells, suggesting that 
P-Rex2B is a Rac specific GEF in vivo. Although PDGF stimulation can cause membrane 
ruffling, the presence of P-Rex2B caused aggressive membrane ruffling with more 
undulating membrane [Fig. 4B panel f]. This is similar to what we have observed in cells 
expressing dominant activated Rac [data not shown]. This is also consistent with what was 
previously seen with P-Rex2A [Raji E. Joseph and Frank A. Norris, unpublished data]. 
Immunolocalization of P-Rex2B showed that it is mainly cytosolic with some plasma 
membrane staining [Fig.4B panel e]. Moreover, there were no major changes in the 
localization of the protein upon stimulation with PDGF. Thus, both P-Rex2A and P-Rex2B 
are growth factor-dependent Rac specific GEFs in vivo. 
The role of the phosphatase-like domain of both P-Rexl and P-Rex2 still remains 
elusive. P-Rex2B did not differ from P-Rex2A in its ability to activate Rac mediated ruffling 
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in vivo. Moreover, we have previously obtained a similar result with a deletion construct of 
P-Rex2A without the phosphatase domain [Raji E. Joseph and Frank A. Norris, unpublished 
data]. This indicates that the phosphatase domain of P-Rex2A does not influence Rac 
activation in this ruffling assay. However, it does not exclude the possibility that the 
phosphatase domain may regulate other Rac mediated processes. 
Lipid binding analysis ofP-Rex2B 
The PH domain of P-Rex2A was shown previously to interact preferentially with 
phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)Pz) and PtdIns(3,4,5)Ps [Raji E. Joseph 
and Frank A. Norris, unpublished data]. In order to determine whether the lipid binding 
properties of full-length P-Rex2B differed from that of the PH domain alone, we assessed the 
lipid binding properties of full length P-Rex2B using a lipid overlay blot. As shown in Fig. 
5A, P-Rex2B had a broader lipid binding capability than what has been previously reported 
for the PH domain alone, and interacted with all of the phosphorylated inositol lipids on the 
blot. This suggested that there were additional lipid binding modules within P-Rex2B. 
The DEP domains of other proteins have been shown to mediate membrane 
association [22,23,24,30]. Sequence alignments of the two DEP domains of P-Rex2 with the 
DEP domains of other proteins show the maintenance of conserved features [Fig. 5B], The 
key residues involved in stabilizing the tertiary structure by hydrophobic interactions, are 
well conserved in both the DEP domains of P-Rexl and P-Rex2 [Fig. 5B, boxed amino acids 
in HI, H2 and H3]. The two conserved glycine residues present on either end of the (3-hairpin 
'arm', allow for the sharp bends in the polypeptide chain [indicated by arrows in Fig. 5B], 
Interestingly, the glycine residues are not maintained in the DEP2 domain of P-Rex2. 
However, the proline residue that has replaced the glycine could potentially serve the same 
function. 
The structure of the DEP domain of Dishevelled revealed the presence of a highly 
positively charged surface that was suggested to interact with negatively charged lipids [19]. 
These basic residues are also maintained in the two DEP domains of P-Rex2 [indicated by 
asterisks in Fig. 5B]. To determine whether the DEP domains of P-Rex2B were involved in 
lipid binding, they were purified and their lipid binding property was tested. As shown in Fig. 
5C, the DEP domains were able to interact with all phosphorylated inositol lipids tested, 
consistent with the broad lipid binding ability of the full-length P-Rex2B. Interestingly, the 
binding is selective for phosphorylated inositol lipids, as it did not bind to other anionic lipids 
such as phosphatidylinositol, phosphatidylserine and phosphatide acid. The phosphoinositol 
lipid binding ability of the DEP domains were also confirmed by vesicle pull down assays, 
which showed that they could bind to phosphatidylinositol 4-phosphate and 
phosphatidylinositol 4,5-bisphosphate, but not to phosphatidylcholine (data not shown). To 
our knowledge, this is the first demonstration that DEP domains can function as lipid-binding 
domains. The DEP domains of P-Rex2 may work in conjunction with the PH domain to aid 
in the localization of P-Rex2. 
Other lipid binding modules like PH domains, C2 domains and PX domains also 
interact with phosphorylated inositol lipids [31]. However, lipid binding by these domains is 
mediated by basic residues present on extended loops, which form a binding pocket for the 
lipid. The structure of the DEP domains show that they do not have such extended loops 
associated with it [19,21], Further experiments will be needed to determine how the DEP 
domains interact selectively with these lipids. 
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CONCLUSIONS 
Comparison of the guanine nucleotide exchange properties of P-Rex2A and P-Rex2B 
show that they did not differ from each other in vitro. The phosphatase-like domain of 
P-Rex2 also does not influence the ability of Rac to form membrane ruffles in vivo. 
Activation of Rac, apart from cytoskeletal changes, causes changes in gene expression, cell 
proliferation, migration and oxidative stress biology [2,3,4], The impact of the phosphatase-
like domain on these other functions remains to be evaluated. Furthermore, we demonstrate 
that the DEP domains of P-Rex2 interact specifically with phosphorylated inositol lipids. 
Binding of lipids by the DEP domains of P-Rex2 and other proteins may aid in their 
localization or in the regulation of their activity. 
P-Rexl plays a crucial role in stimulating neutrophil oxidative burst by activating 
Rac, a component of the neutrophil oxidase complex [11]. Intriguingly, a non-phagocytic 
oxidase complex has been identified in skeletal muscles, however its function remains 
unclear [32]. Future experiments will assess whether P-Rex2B can regulate the activity of 
this oxidase complex. P-Rex2B is mainly expressed in skeletal muscles and heart and may 
serve to integrate both heterotrimeric G protein signaling and phosphoinositide 3-kinase 
signaling in these tissues. The functional consequences of Rac activation by P-Rex2B in 
response to these signals in these tissues remain to be explored. 
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FOOTNOTES 
The nucleotide sequence for human P-Rex2B gene has been deposited in the 
GenBank database under GenBank Accession Number AY508997. 
ABBREVIATIONS 
IP4P, inositol polyphosphate 4-phosphatase; PI3K, phosphoinositide 3-kinase; 
PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-trisphosphate; GEF, guanine nucleotide exchange 
factor; DH, Dbl homology; PH, pleckstrin homology; GFP, green fluorescent protein; mant-
GDP, N-methylantranioyl-GDP; PDGF, Platelet derived growth factor; FITC, fluorescein 
isothiocyanate; RACE, rapid amplification of cDNA ends; GST, glutathione S-transferase; 
HRP, horseradish peroxidase; PBS, phosphate buffered saline. 
FIGURE LEGENDS 
FIG. 1: Structure of P-Rex2B. 
(A) Amino acid sequence of P-Rex2B. The alternate spliced region is boxed (GenBank 
accession # AY508997). (B) Domain architecture comparison of P-Rex2A and P-Rex2B. 
The alternately spliced region in P-Rex2B is indicated as a hashed box. (C) Chromosome 
organization of P-Rex2. Schematic of the gene structure of human P-Rex2 with 41 exons. 
The alternate splice variant, P-Rex2B is formed using ex on 24. 
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FIG. 2: Tissue distribution of P-Rex2B. 
Multi-tissue northern blots (CLONTECH) of human P-Rex2B using polyA mRNA isolated 
from the indicated tissues, show three transcripts of ~5kb, 6kb and 8kb (indicated with 
asterisks). 
FIG. 3 In vitro GEF activity of P-Rex2B. 
The GEF activity of P-Rex2B was monitored by the increase in fluorescence associated with 
the binding of Mant-GDP by Rac. The intrinsic rate of exchange of Racl alone is shown with 
filled circles. The effect of addition of P-Rex2B to Racl in the presence of mixed 
phospholipid liposomes without PtdIns(3,4,5)Ps (open circles), phospholipid liposomes with 
5pM PtdIns(3,4,5)P3 (filled squares), 0.4|iM Gpy subunits (open squares), 5|lM 
PtdIns(3,4,5)P3 and 0.4|iM G (By subunits (open triangles) is indicated. 
Fig. 4 In vivo GEF activity of P-Rex2B. 
(A) Immunofluorescence micrographs of double labeled P-Rex2B or GFP transfected NIH 
3T3 cells. NIH 3T3 cells were transfected with V5-tagged P-Rex2B or GFP expression 
constructs, serum starved (c, d) and then stimulated with 10ng/ml PDGF (a, b, e, f). The cells 
were stained for protein using anti-GFP antibody (a) or anti-V5 antibody (c, e). Rhodamine 
phalloidin was used to detect actin (b, d, f). (B) Quantification of fluorescence microscopy 
data. Fifty GFP or P-Rex2B transfected cells were assessed for the formation of membrane 
ruffles under the following conditions: (1) GFP without PDGF, (2) P-Rex2B without PDGF, 
(3) GFP with PDGF, (4) P-Rex2B with PDGF. 
77 
FIG. 5: Lipid binding properties of P-Rex2B. 
(A) Purified GST-tagged full-length P-Rex2B or (C) GST-tagged DEP1DEP2 domains of 
P-Rex2B were incubated with a phospholipid overlay blot (Echelon Inc.). Binding was 
detected using an anti-GST antibody coupled with a chemiluminescent detection system. 
(B) Sequence alignment of the DEP domains of P-Rex2 with other DEP domains. The 
conserved hydrophobic residues are boxed, arrows indicate the conserved glycine residues 
and the conserved basic residues are indicated with asterisks. 
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TABLE 1: Gene structure of P-Rex2. 
Table showing the intron-exon boundaries of P-Rex2. a, 5' exon boundary is defined as the 
start ATG; b, alternate spliced exon; c, 5' intron boundary is not determined (ND) and is 
defined by the stop codon. 
Exon Exon boundary Exon Intron Intron boundary Intron 
no. 5' 3' length no. 5' 3' length 
1' ATGAGCGAG CTGGTGTCG 141 1 gtgagtgtc ttcatgcag 65310 
2 GCATTCTTA ACAGTGAAG 72 2 gtgaggagg tatttacag 1631 
3 ATGTTGTTC CTTCACTTT 123 3 gtaggataa aattcacag 2364 
4 AAAGACAAG TTTCTTTTG 105 4 gtaagtgta tcaccccag 5081 
5 AACTGCATG ATTTTGAAG 102 5 gtattttat tataaacag 3173 
6 GAGTTGCTG GGCTGGGAG 162 6 gtacattca ctgacttag 7500 
7 GGGTCCAAC AAAACACAG 134 7 gtaagatcc catcttaag 6194 
8 ACGGTTGAA ATGGCACCG 104 8 gtaagtgat aatttacag 8506 
9 CTGATTTCC GGCGGAAAG 150 9 gtgggtgta ttttgatag 2583 
10 GTTTAAAAT TCTTGGAAG 145 10 gtagggttg ctcttgcag 4704 
11 CGAATTTGT TTCACCATG 101 11 gtaattact tgttcttag 8253 
12 TTACTGATA ATTTCAAAG 104 12 gtaacgacc tttacgtag 698 
13 GGTGTAAGA AGTGATAAG 50 13 gtgagtctg cctttatag 2610 
14 AGATAAAGA ATTGCACAG 76 14 gtaaataga ggttaacag 4826 
15 GGAGATTGC TGCACCATG 73 15 gtagggatt ttlctgtag 2973 
16 TCCTTGAAA TCATTATTG 143 16 gtaagttta gcatttcag 160 
17 ATTAAATCC AATGCTGAG 93 17 gtaagttaa ctctcttag 2401 
18 ATGGCTGGC GCCAAGAGA 149 18 gtaagttgt ttgatttag 4335 
19 GACAGTGAA TAGGAAGAG 86 19 gtaggaaat tatttatag 2769 
20 GAACTGTGG CCAACGAAG 137 20 gtaagtggc catttccag 2889 
21 CAAGATTCC AAGTAGAAG 118 21 gtaggtttc ttgttccag 3294 
22 AGGTTATTG ACTGCCAAG 185 22 gtaggagcg tcattgcag 2480 
23 ATTCTTGAA TAT AAA A AG 162 23 gtaagtgtt atattttag 5294 
24" GTTCAAGCT CCTGTCTGA 225 24 ND' aatttgcag NDC 
25 TTTTCTCGT CGGAGCAAG 223 25 gtatgctag attcctcag 1084 
26 GGAAACTGA AATAGATGA 208 26 gtaagtgtt acattgcag 6129 
27 CCTTCTGTC CTCTTACAG 180 27 gtaattcac tgttttcag 2617 
28 TGACTGCAA TGGACTCAG 95 28 gtgtgttcg gacatctag 787 
29 GTGATGAAC TTCAGCCAG 83 29 gtacaatcg tattgatag 681 
30 GTGGATTCA GATTGCAAG 91 30 gtaagcctt tttatttag 634 
31 AATTTCAAC TTGTTGAAG 129 31 gtcagcatg tctctgcag 6328 
32 AAGTAAAGT AATAATCAG 42 32 gtaacattt tgatcacag 6639 
33 ATAGTGAGA CCAAACTTG 218 33 gtaaggaaa tctttgtag 4137 
34 ACAGATGAA TGGTTGCAA 103 34 gtaagtaat tcattttag 7691 
35 ATGTTCCTC TTGCACAAG 144 35 gtaaactgt tttacacag 10969 
36 CACTAGAGA GAAGCTCAG 115 36 gtatgtaac ttcttacag 34284 
37 GGCATTCTA GTAGATAAG 67 37 gtaaaaaca tttctgcag 546 
38 CTAATGAGG TGTGCATCG 191 38 gtatgtgac ggcccacag 25091 
39 GTGCACCCT CGGAAGCAG 103 39 gtaggtctc gactttcag 6840 
40 GGAGCAAGA TGCACCAAG 68 40 gtaagtgca cttttctag 6706 
41 GCTGTACAA GAAGAATGA 46 41 ND1' 
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TABLE 2: Initial rates of guanine nucleotide exchange reactions catalyzed by P-Rex2B on 
Racl. 
Rate Fold 
104 (Rel. fluorescence units/sec) Activation 
Racl 1.73 
Racl + P-Rex2B 3.32 1,91 
Racl+P-Rex2B+0.4piM GJBy 16.20 9.36 
Racl+ P-Rex2B+ 5piM PtdIns(3,4,5)P3 16.02 9.26 
Racl+ P-Rex2B+ 0.4|xM G(3y+ 5|iM 
18.68 10.79 
PtdIns(3,4,5)P3 
The initial rates of guanine nucleotide exchange for 2|xM Racl catalyzed by 0.1 pM P-Rex2B 
were determined by linear regression analysis of approximately the first 100 seconds of each 
reaction. The fold activation reflects the ratio of the initial rate for the P-Rex2B containing 
reaction to the intrinsic rate of exchange for Racl. 
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SUBSTRATE SPECIFICITY AND RECOGNITION IS CONFERRED BY 
THE PH DOMAIN OF THE DBL FAMILY GUANINE NUCLEOTIDE 
EXCHANGE FACTOR P-REX2. 
A paper to be submitted to The Journal of Biological Chemistry 
Joseph, R.E.1 and Norris, F.A.* 
SUMMARY 
Dbl family guanine nucleotide exchange factors (GEFs) are characterized by the 
presence of a catalytic Dbl homology (DH) domain followed invariably by a lipid binding 
pleckstrin homology (PH) domain. To date, substrate recognition and specificity of this 
family of GEFs has been reported to be mediated exclusively via the DH domain. Here we 
report the novel and unexpected finding that the PH domain of the Dbl family Rac specific 
GEF P-Rex2, confers substrate specificity and recognition. Moreover, we demonstrate that 
the (33(34 loop of the PH domain of P-Rex2 is the determinant for Racl recognition as 
deletion of this loop disrupts the interaction with Racl. Furthermore, substitution of the (33(34 
loop of the PH domain of Dbs, a RhoA and Cdc42 specific GEF, with that of P-Rex2, confers 
Racl specific binding capability to the PH domain of Dbs. The contact interface between the 
PH domain of P-Rex2 and Racl involves the switch loop and helix 3 of Racl. Moreover, 
substitution of helix 3 of Cdc42 with that of Racl, now enables the PH domain of P-Rex2 to 
bind this Cdc42 chimera. Despite the ability to recognize this chimeric Cdc42, P-Rex2 is 
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unable to catalyze exchange on it, suggesting that recognition of substrate and catalysis are 
two distinct events. Thus substrate recognition can now be added to the growing list of 
functions that are being attributed to the PH domain of Dbl family GEFs. 
1 Primary researcher and author. 
* Author for correspondence. 
INTRODUCTION 
The Rho family of G proteins are members of the Ras superfamily (1,2). A hallmark 
of G proteins is their ability to undergo conformational changes upon binding to either GTP 
or GDP. These G proteins therefore function as binary switches, as different partner proteins 
within the cell recognize the GTP-bound 'on' state and the GDP-bound 'off' state of the 
protein. They are activated by guanine nucleotide exchange factors (GEFs), which exchange 
GDP for GTP. There are 20 Rho family members identified to date, with RhoA, Racl and 
Cdc42 being the most well characterized members (3). They carry out a wide and diverse 
range of functions from regulating the actin cytoskeletal network to the neutrophil oxidative 
burst (4,5). 
Dbl family GEFs catalyze nucleotide exchange on the Rho subfamily of small G 
proteins (6,7). Dbl was first isolated as an oncogene from a diffuse B cell lymphoma (8). 
Since then its characteristic 300 amino acid sequence has been identified in over 60 
mammalian proteins, making this one of the largest family of oncogenes (6,9). This 300 
amino acid stretch is subdivided into a Dbl homology (DH) domain, followed invariably by a 
pleckstrin homology (PH) domain. Beyond the DH/PH domains, Dbl family members share 
little sequence similarity with each other (6,7,9). 
The DH domain consists of -200 amino acids and is the catalytic domain (10). 
Within the DH domain are three highly conserved regions referred to as conserved regions 1, 
2 and 3 (CRI, CR2 and CR3) (7). The structure of several Dbl family members shows that 
the DH domain consists of an elongated helical bundle, with the CRI, CR2 and CR3 forming 
long helices that pack together to form the core of the module (11,12,13). PH domains are 
lipid-binding domains that are found in a wide variety of signaling molecules (14,15,16). It 
consists of a seven-stranded (3-sandwich that is capped on one end by a C-terminal a-helix 
(14). The invariant association of the PH domain with the DH domain in all Dbl family 
members suggests a functional interdependence between these modules. These PH domains 
have been shown to mediate membrane association and to modulate the activity of the DH 
domain (17,18,19, 20,21). 
Dbl family members vary widely in their substrate specificity. GEFs like Tiaml and 
Trio catalyze exchange only on Racl (22), Dbs and Dbl are able to activate both Cdc42 and 
RhoA (23), while Vavl and Vav2 catalyze exchange on RhoA, Racl and Cdc42 (24). The 
structural basis for this recognition process is only beginning to be understood (25). The 
crystal structures of the Racl-Tiaml, Cdc42-Dbs, Cdc42-RhoA and Cdc42-Intersectin 
(ITSN) complexes show that the CRl and CR3 regions of the DH domain of the GEF makes 
extensive contact with the (32(33 strands of the GTPases (25,26,27,28,). These regions were 
therefore predicted to determine the specificity of these interactions. Based on these crystal 
structure complexes, Trp 56 of Racl, was isolated as one of the critical residues for 
recognition by Rac specific GEFs (27). Mutation of this residue to Phe, the corresponding 
residue in Cdc42, was sufficient to abolish binding by Tiaml. Moreover, this mutant Racl 
could now be recognized by ITSN, a Cdc42 specific GEF. While this region clearly 
determines the specificity of some of these interactions, it cannot explain the specificity of all 
GEF-GTPase interactions (25). Moreover, the contribution of the PH domain in these 
interactions have remained unexplored. 
P-Rexl was isolated from neutrophils based on its activity as a Rac specific GEF 
(29). Its activity was conditional on the presence of phosphatidylinositol 3,4,5-trisphosphate 
(Ptdlns (3,4,5)P3) or Gpy subunits. It plays a crucial role in stimulating the neutrophil 
oxidative burst (29). Biochemical characterization of P-Rex2, a homologue of P-Rexl, 
showed that it also was a Rac specific GEF (Joseph R.E and Norris F.A., manuscript 
submitted). In this report we show that P-Rex2 recognizes Racl in an unusual way. The 
specificity of this interaction is conferred by the PH domain of P-Rex2 and not by the DH 
domain: This function has never before been attributed to the PH domain of a Dbl family 
GEF. Moreover, we demonstrate that the (33(34 loop of the PH domain is necessary and 
sufficient to confer this specificity. The PH domain makes contact with the switch loop and 
helix 3 of Racl. While helix 3 of Racl is sufficient to confer recognition, it is not sufficient 
for catalysis, suggesting that substrate recognition and catalysis are two distinct functions. 
EXPERIMENTAL PROCEDURES 
Materials 
Wild type bacterial expression construct for RhoA was created by PGR amplification 
and cloned into the Smal/NotI sites of pGEX 4T-1 (Amersham Pharmacia Biotech). Bacterial 
expression constructs for Racl and Cdc42 were kind gifts from Gary Bokoch. The DH/PH 
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domains of Dbl and the PH domain of Dbs was PGR amplified from human mammary cDNA 
library (CLONTECH), and cloned into the pcDNA3.1D V5-His-TOPO vector (Invitrogen). 
The DH domain (residues 22 to 231), the PH domain (residues 241 to 370) and the DH/PH 
domains of P-Rex2 (residues 22 to 370) were cloned into pcDNA3.1D V5-His-TOPO vector 
by PGR. The (33(34 loop deletion (amino acid residues 277 to 296), mutant of the PH domain 
of P-Rex2 and the RaclW56F mutant were created by using the QuikChange™ Site-Directed 
Mutagenesis Kit from Stratagene, according to the manufacturers protocol. The Dbs/P-Rex2 
(33(34 loop chimeric PH domain was created by PGR as follows. The 5' end of the chimera 
was created by PGR using oligonucleotides 
5'-CACCATGCTGCTGATGCAGGGCTCATTCAGC-3' (sense) and 5'-
CATCTGTAGATGCCTTGCTGTTCTTCAACCGTCTGTGTTTTCTCTCCCTCTTCTTGC 
AGAAGAG-3' (antisense). The 3' end of the chimeric gene was amplified using 
oligonucleotides 5'-
GAACAGCAAGGCATCTACAGATGGACATCGGTACCTTTTTTCCTACAGCTACAAG 
CAGTCC-3' (sense) and 5'-CAGGCTCTGTGACTGCTCCAG-3' (antisense). The 5' and 3' 
ends of the gene obtained by PGR were purified and were amplified together by PGR using 
oligonucleotides 5' -CACGATGCTGGTGATGCAGGGCTCATTGAGC-3 ' (sense) and 
5'-CAGGCTCTGTGACTGCTCCAGCGC-3' (antisense). The full-length PGR product was 
subsequently purified and cloned into the pcDNA3.1D V5-His-TOPO vector by TOPO 
cloning. The bacterial expression construct for Cdc42Raclhelix3 chimeric was created by 
PGR as follows. The 5' end of the chimeric was created by PGR using oligonucleotides 
5 ' -GATCTGGTTCCGCGTGGATCCAAAATTATTTCAGC-3 ' (sense) and 
5 ' -CC ACTTTTCTTTC ACGTTTTC AA ATG A AG ATGG ACTC AC A AGGG-3 ' (antisense). 
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The 3' end of the chimera was created by PGR using oligonucleotides 
5 ' -GTGAAAGAA AAGTGGGTGCCTG AG AT AACTC ACC ACTGTCCCAAC-3 ' (sense) 
and 5'-TCAGTCAGTCACGATGAATTCATCTGTCGACTG-3' (antisense). The 5' and 3' 
end PGR products were purified, mixed together and the full-length chimera was created by 
PGR using oligonucleotides 5 ' -GATCTGGTTCCGCGTGG ATCC A A AATTATTTC AGC-3 ' 
(sense) and 5 ' -TC AGTC AGTC ACGATG AATTC ATCTGTCGACTG-3 ' (antisense). The 
PGR product was digested with BamHl and EcoRl and was ligated into the pGEX-2T vector 
(Amersham Pharmacia Biotech) cut with the same enzymes. 
Purification of Proteins 
GST and GST-tagged Racl, RhoA, and Cdc42 were expressed and purified from 
Escherichia coli as described elsewhere (30). 
Complex Formation Assay 
The complex formation assay was performed essentially as described (31). The 
DH/PH domains of P-Rex2, Dbl or Dbs were labeled with [35]S Met using rabbit reticulocyte 
lysate coupled transcription translation system (Promega) for 90min at 30°C in a total 
reaction volume of IOjaI, as per the manufacturers instruction. 2|il of this reaction was then 
incubated with 5|ig of purified GST, GST-Racl, GST-RhoA or GST-Cdc42 in 500gl of 
complex formation assay buffer (20mM Tris pH 7.5; lOOmM NaCl; 2.0mM EDTA; 
0.5%Triton X 100) with 25(0.1 of glutathione sepharose beads (Amersham Pharmacia) for 2hrs 
at 4°C. The beads were spun down and washed five times with the same buffer. The beads 
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were then boiled in SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE, 
followed by western transfer and autoradiography. 
Racl was loaded with GDP or GTPyS as described earlier (31). Briefly, 12.5 pM of 
purified GST-Racl was incubated with 20 |iM GDP or GTPyS in loading buffer (lOmM 
Hepes pH 7.5, lOOmM NaGl, 7.5mM EDTA) at 23°C for 25 min. The complexes were 
stabilized using 20mM MgCb- 5pig of the loaded protein was then used for the complex 
formation assay in a modified complex formation assay buffer with 20mM MgGla instead of 
2.0mM EDTA. 
Guanine nucleotide exchange assay 
The in vitro GEF assay was performed on a Mithras LB 940 (Berthold Technologies) 
fluorescence spectrophotometer by modifying a basic protocol described elsewhere (32). 
2}iM of purified GST-tagged Rho family G protein was incubated with lOOnM of purified 
GST-tagged P-Rex2A and 400nM Mant-GDP (Molecular Probes) in 50p,l of exchange buffer 
(20mM Tris, pH 7.5, 50mM NaGl, lOmM MgGl2, ImM DTT, 50^1 BSA and 10% 
glycerol). Excitation and emission wavelengths were 355nm and 460nm, respectively. 
RESULTS 
The Racl W56F mutation does not affect P-Rex2 binding. 
Comparison of the crystal structure complexes of Tiaml and Racl with other Rho 
GTPase-GEF complexes have identified the Trp 56 residue of Racl as a key determinant of 
specificity for Rac specific GEFs (27). This residue was shown to interact with a conserved 
lie in the DH domain of Rac specific GEFs. Sequence alignment however, shows that this 
conserved Ile is not present in the DH domain of P-Rex2 or P-Rexl (Fig. 1 A),. As mutation 
of the Trp 56 residue to Phe is sufficient to abolish binding by the DH/PH domain of the 
Racl specific GEF Tiaml, we decided to test whether this mutation had any effect on the 
binding ability of P-Rex2 (27). The DH/PH of P-Rex2 was expressed and labeled with [35]S 
Met using a rabbit reticulocyte lysate system, and tested for its ability to bind this mutant in a 
pull-down assay. As shown in Fig. IB, the RaclW56F mutation does not affect the binding 
ability of the DH/PH of P-Rex2. This suggests that the mode of interaction of P-Rex2 with 
Racl is different from that of other Racl specific GEFs. 
Substrate recognition occurs via the PH domain ofP-Rex2. 
Dbl family GEFs are characterized by the presence of an invariant DH/PH domain. 
Substrate recognition by this family of GEFs is thought to be mediated exclusively by the 
DH domain (25,26,27,28). P-Rexl and P-Rex2 have been previously reported to specifically 
catalyze exchange on Racl (29, Joseph R E. and Norris F.A., manuscript submitted). To 
determine the domain which confers this specificity, the DH, PH, and DH/PH domains of 
P-Rex2 were expressed and labeled with [35]S Met using a reticulocyte lysate, and tested for 
its ability to interact with RhoA, Racl, and Cdc42 in a pull-down assay. The DH/PH domain 
of Dbl, which has the capacity to interact with all three G proteins was used as a positive 
control. As shown in Fig. 2, surprisingly the PH domain alone of P-Rex2 is able to 
specifically interact with Racl while the DH domain alone of P-Rex2 is unable to do so. This 
is the first demonstration of the ability of a PH domain of a Dbl family GEF to specifically 
recognize its G protein substrate. 
The @3/34 loop region of the PH domain ofP-Rex2 is required for Racl interaction. 
The crystal structure of the Dbs in complex with Cdc42 shows that the PH domain of 
Dbs has an extended 03(34 loop which makes contact with the switch loop 2 and helix 3b of 
Cdc42 (28). Alignment of the PH domain of P-Rex2 with other PH domains, including that 
of Dbs and P-Rexl, shows that P-Rex2 PH domain also has an extended (33(34 loop (Fig. 
3A). To determine whether this loop of P-Rex2 makes contact with Racl, a (33(34 loop 
deletion mutant of P-Rex2 PH domain was tested for its ability to bind Racl as before. As 
shown in Fig. 3B, the (33(34 loop deletion mutant of P-Rex2 PH domain showed an 80% 
reduction in its ability to bind Racl. This suggests that the (33(34 loop of the PH domain of 
P-Rex2 is involved in the interaction with Racl. 
The 03/34 loop region of the PH domain ofP-Rex2 is the determinant of Rac interaction. 
Although deletion of the (33(34 loop of the PH domain of P-Rex2 abolishes Racl 
binding, it is possible that this mutation could affect the overall structure of the PH domain. 
The Dbl family GEF Dbs is able to catalyze exchange specifically on RhoA andCdc42. 
Moreover, the crystal structure of Dbs in complex with Cdc42 shows that its PH domain 
(33(34 loop makes limited contact with Cdc42 (28). Our binding studies with the PH domain 
alone of Dbs shows that it is incapable of interacting with RhoA, Racl and Cdc42 (Fig. 4). In 
order to determine whether the (33(34 loop of the PH domain of P-Rex2 would be sufficient to 
confer Racl recognition, we created a chimeric PH domain in which the (33(34 loop region of 
the Dbs PH domain had been substituted with that of P-Rex2. As shown in Fig 4, this 
chimeric PH domain was able to specifically interact with Racl. This demonstrates that the 
(33(34 loop of the PH domain of P-Rex2 is the determinant for Racl interaction. 
The switch loops of Rac make contact with the PH domain ofP-Rex2. 
The crystal structure of Dbs in complex with Cdc42 shows that its PH domain makes 
contact with the switch loop2 of Cdc42 (28). To test whether the PH domain of P-Rex2 also 
makes this contact, purified GST-tagged Racl was loaded with GDP or GTPyS and tested for 
its ability to bind to the PH domain in a pull-down assay as before. As shown in Fig. 5, the 
PH domain of P-Rex2 makes contact with a switch loop, as the nucleotide bound forms of 
Racl showed a dramatic reduction in its ability to bind the PH domain. 
Helix 3 of Rac is the determinant for specificity for the binding of the PH domain ofP-Rex2. 
The crystal structure of Cdc42 with Dbs shows that the PH domain makes contact 
with helix 3b of Cdc42, a region adjacent to the switch loop 2 of Cdc42 (28). Moreover, the 
primary sequence of helix 3 differs between Racl and Cdc42 (Fig. 6A). To determine 
whether this helix in Racl makes contact with the PH domain, helix 3 of Cdc42 was 
substituted with that of Racl and this chimeric Cdc42 was tested for its ability to interact 
with the PH domain. As shown in Fig. 6B, the PH domain of P-Rex2 was able to recognize 
the chimeric Cdc42 with helix 3 of Racl. This demonstrates that the determinant for Racl 
recognition by the PH domain of P-Rex2 lies in helix 3. 
P-Rex2A does not catalyze exchange on Chimeric Cdc42 with helix 3. 
Binding experiments have demonstrated that P-Rex2 via the PH domain can interact 
with a chimeric Cdc42 with Racl helix 3. To determine whether binding to the chimeric 
Cdc42 is sufficient for catalysis, we tested the ability of P-Rex2A to catalyze exchange on 
this chimeric Cdc42 in an in vitro exchange assay under conditions where P-Rex2A could 
catalyze exchange on Racl. As shown in Fig. 7, P-Rex2 is unable to catalyze exchange on 
the chimeric Cdc42. This chimera did not differ from wild-type Cdc42 in its ability to load 
Mant-GDP (data not shown). This suggests that binding ability does not necessarily predict 
catalytic ability, as the two events seem to be distinct from each other. 
DISCUSSION 
Activation of Dbl family GEFs in vivo lead to the activation of specific G protein 
signaling pathways (6). This specificity hinges on the ability of the GEFs to discriminate 
among the different G proteins present within the cell. Elucidation of the determinants of 
specificity of interaction between Dbl family GEFs and their cognate Rho GTPases is 
therefore of critical importance and has been one of the major areas of focus in research 
recently. The crystal structures of Tiaml, Dbs and ITSN with Racl, Cdc42/RhoA, or Cdc42 
respectively have made a major breakthrough in isolating some of the critical residues that 
determine the specificity of these interactions (25,26,27,28). However, attention has been 
focused on the DH domain in particular, as it was found to make major contact with the 
GTPase. Alignment of the primary sequence of the DH domain of Racl specific GEFs have 
identified a conserved lie residue that makes contact with Trp 56 of Racl. Discrimination 
between Cdc42 and Racl was thought to be mediated through this Trp residue as the 
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corresponding residue in Cdc42 is a Phe. However, the RaclW56F mutation had no effect on 
the binding ability of the DH/PH domain of P-Rex2 (Fig.l). Surprisingly, the DH domain 
alone was incapable of binding Racl. As the DH domain is the catalytic domain and P-Rex2 
is a Racl specific GEF, it suggests that the DH domain may have to undergo conformational 
rearrangements in order for it to catalyze exchange on Racl. 
Although Dbl family GEFs are characterized by the presence of a DH/PH domain, it 
is becoming increasingly clear that these PH domains are quite unlike PH domains found in 
other signaling proteins. In addition to membrane targeting function by binding lipids, they 
have been shown to have other diverse roles (28). The activity of the DH domain of Trio is 
increased a 100 fold by the presence of the PH domain (12). Lipid binding by the PH 
domains of Vav, Sos and Tiaml have been shown to modulate the activity of the DH domain 
both in vitro and in vivo (33,34). Mutations in the PH domain which affect lipid binding has a 
big impact on the activity of the GEF in vivo, in a manner which cannot be explained solely 
on differences in localization of the protein (35). The PH domain of Dbs makes contact with 
the switch loop 2 and helix 3b of Cdc42. Disruption of these interactions by the PH domain 
has a significant impact on the ability of Dbs to catalyze exchange on Cdc42 (28). The PH 
domain of Dbs was also recently shown to be an effector for Racl, as it could bind to the 
GTP bound form of Racl (36). Our own binding studies with the PH domain of P-Rex2 
showed the surprising result that the PH domain is responsible for substrate selectivity and 
recognition. This is the first instance where this function has been attributed to the PH 
domain of a Dbl family GEF. The (33(34 loop region of the PH domain of Dbs makes contact 
with Cdc42 in the Dbs-Cdc42 complex. Interestingly, the same loop of the PH domain of 
P-Rex2 was shown to be necessary and sufficient for the interaction with Racl. Although the 
PH domain of some Dbl family GEFs like Dbs do not independently bind to their cognate 
GTPases, additional experiments will be required to test the PH domains of other Dbl family 
GEFs. 
P-Rex2 could select for Racl via its PH domain. The PH domain recognizes Racl by 
interacting with the switch loop and helix 3. Substitution of helix 3 of Cdc42 with that of 
Racl, enabled the PH domain to interact with this chimeric protein. Moreover, it is likely that 
the PH domain of P-Rex2 interacts with switch loop 2 of Racl rather than switch loopl, 
owing to its proximity with helix 3b. Even though P-Rex2 could interact with Cdc42chimera, 
it was unable to catalyze exchange on it. This suggests that substrate recognition and 
catalysis are two distinct events. While the PH domain may recognize the substrate, it is the 
contacts being made by the catalytic DH domain that determine enzymatic activity. Other 
Dbl family GEFs have been previously shown to interact with many GTPases, however they 
could catalyze exchange only on a limited subset of these GTPases. Dbl for example can bind 
to RhoA, Racl and Cdc42, but will catalyze exchange on only RhoA and Cdc42 (37,28). 
Further studies will be required to delineate the contacts that are being made during the PH 
domain mediated substrate binding versus the DH domain mediated catalysis. 
The structure of the DH/PH domain of Dbl family GEFs show that the orientation of 
the PH domain with respect to the DH domain can vary widely (28). The region in between 
the DH and PH domains vary between different GEFs. However, it is this region that 
determines the placement of the PH domain relative to the DH domain. Moreover, the NMR 
structure of Sos shows that this region is extremely flexible (13). This suggests that the 
orientation of the PH domain may be more flexible, and PH domain contacts with the 
cognate GTPase may be a more common occurrence, a feature that may not be appreciated in 
rigid crystal structure complexes. While the crystal structures have clearly shçd a lot of light 
on the mechanism of guanine nucleotide exchange, and the determinants of specificity, it 
clearly is not the whole story. Given that the Rho family GTPases are so conserved, Dbl 
family GEFs may have multiple ways to determine substrate specificity. Future experiments 
will explore the details of these interactions. 
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FIGURE LEGENDS 
FIG. 1: Determinants of specificity of P-Rex2/Racl interaction differ from that of other 
Racl specific GEFs. (A) Alignment of the a5 helix of P-Rex2 with that of other Dbl GEFs. 
The conserved lie residue in Racl specific GEFs is boxed. (B) The RaclW56F mutation does 
not affect the binding ability of the DH/PH domain of P-Rex2. The DH/PH domain of 
P-Rex2 labeled with [35]S Met using a rabbit reticulocyte lysate was tested for its ability to 
bind GST or GST-tagged forms of RaclWT or RaclW56F mutant in a pull-down assay. 
Binding was detected by western blotting followed by autoradiography. 
FIG. 2: Substrate recognition and specificity is conferred by the PH domain of P-Rex2. 
The DH, PH, DH/PH domains of P-Rex2 were labeled with [35]S Met and tested for its ability 
to bind GST or GST-tagged forms of RhoA, Racl or Cdc42 in a pull down assay as before. 
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The DH/PH domain of Dbl was used as a positive control. Binding was detected by western 
blotting followed by autoradiography. 
FIG. 3: The 0304 loop of the PH domain of P-Rex2 is necessary for its interaction with 
Racl. (A) Alignment of the 0304 loop of the PH domain of P-Rex2 with that of other PH 
domains. The predicted secondary structure is based on the crystal structure of Grpl PH 
domain, and is indicated by the two 0-sheets. The conserved Try is boxed. (B) The WT PH 
domain and 0304 deletion mutant of the PH domain of P-Rex2 were labeled with [35]S Met 
and tested for its ability to bind GST or GST-tagged RaclWT in a pull down assay as before. 
Binding was detected by western blotting followed by autoradiography. The binding was 
quantified by densitometry and normalized against that of the WT PH domain. 
FIG. 4: The 0304 loop of the PH domain of P-Rex2 is sufficient for its interaction with 
Racl. The PH domains of P-Rex2, Dbs and the 0304 chimeric PH domain of Dbs were 
labeled with [35JS Met and tested for its ability to bind GST or GST-tagged RhoA, Racl or 
Cdc42 in a pull down assay as before. Binding was detected by western blotting followed by 
autoradiography. 
FIG. 5: The PH domain of P-Rex2 interacts with the switch loops of Racl. GST-tagged 
Racl was loaded with GTPyS or GDP and tested for its ability to interact with the PH domain 
of P-Rex2 as before. The PH domain of P-Rex2 showed diminished binding to the GTPyS or 
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GDP loaded form of Racl as compared to the nucleotide free form of Racl (RaclNF). 
Ponceau S staining of the western blot shows protein levels. 
FIG. 6: Helix 3 of Racl confers specificity to the interaction between Racl and the PH 
domain of P-Rex2. (A) Alignment of helix 3 of Racl with that of Cdc42. (B) The PH 
domain of P-Rex2 was tested for its ability to bind to GST, or GST-tagged forms of Racl, 
Cdc42 and the Cdc42 chimera as before. Ponceau S staining of the western blot shows 
protein levels. 
FIG. 7: P-Rex2 does not catalyze exchange on Cdc42 chimera. In vitro GEF activity of 
P-Rex2 was monitored by the increase in fluorescence associated with the binding of Mant-
GDP by Racl or Cdc42 chimera. The blanks for Racl and Cdc42 chimera are indicated by 
filled triangles and open circles respectively. The effect of addition of P-Rex2A along with 
0.4pM Gpy subunits to Racl (filled squares) or Cdc42 chimera (open triangles) is shown. 
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REGULATION OF P-REX2 VIA AN INTRA MOLECULAR 
INTERACTION BETWEEN THE PDZ, DEP AND PH DOMAINS. 
A paper to be submitted to The Journal of Biological Chemistry 
Joseph, R.E. and Noms, F.A.* 
summary 
P-Rex2 is a Rac specific GEF with an unusual but complex domain architecture 
composed of an N-terminal DH/PH domains, two DEP domains and two PDZ domains. Its 
GEF activity is conditional on the presence of phosphatidylinositol 3,4,5-trisphosphate or 
G0y subunits. The PDZ domains of P-Rex2 are involved in an intra-molecular interaction 
involving the DEP domains and the PH domain. This is the first demonstration of an 
interaction between a DEP domain and a PDZ domain. Furthermore, binding of the PDZ 
domain to the 0304 loop region of the PH domain obscures the Rac binding site on the PH 
domain of P-Rex2. Deletion of the PDZ2 domain restores Rac binding capability in vitro and 
truncation mutants which lack the PDZ domains have enhanced activity in vivo. Thus, the 
inactivity of full-length P-Rex2 is due to its inability to interact with Rac. 
'Primary researcher and author. 
Author for correspondence. 
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INTRODUCTION 
The P-Rex family of proteins are Dbl family guanine nucleotide exchange factors 
(GEFs) that catalyze nucleotide exchange specifically on Rac (1, Joseph, R.E. and Norris, 
F.A., manuscripts submitted). Human P-Rex 1 was originally isolated based on its activity 
from neutrophils where it plays a key role in regulating the oxidative burst (1). P-Rex2 
undergoes alternate splicing to generate two transcripts: P-Rex2A and P-Rex2B (Joseph, R.E. 
and Norris, F.A., manuscripts submitted). P-Rex 1 and P-Rex2A have an unusual domain 
architecture with an N-terminal DH/PH domain, two DEP domains, two PDZ domains and a 
C-terminal inositol polyphosphate 4-phosphatase (IP4P)-like domain. P-Rex2B is a shorter 
splice variant that lacks the C-terminal IP4P-like domain (1, Joseph, R.E. and Norris, F.A., 
manuscripts submitted). 
The DH/PH domains are a characteristic feature of Dbl family GEFs (2,3,4). The Dbl 
homology (DH) domain is approximately 200 amino acids and is the catalytic domain. The 
pleckstrin homology (PH) domain consists of -100 amino acids and is a lipid binding domain 
found in a wide variety of signaling proteins (5,6). It consists of a seven-stranded ^-sandwich 
that is capped on one end with a C-terminal a-helix (7). The PH domains of Dbl family 
GEFs have been shown to be involved in a wide range of functions including membrane 
targeting and in the regulation of the activity of the DH domain (8,9,10,11,12). The PH 
domain of P-Rex2 however is unique. The ability of P-Rex2 to interact specifically with 
Racl is mediated via its PH domain (Joseph, R.E. and Norris, F.A., manuscript submitted). 
This function had previously never been attributed to the PH domain of a Dbl family GEF. 
Moreover, the 0304 loop of the PH domain of P-Rex2 was necessary and sufficient for this 
interaction (Joseph, R.E. and Norris, F.A., manuscript submitted). 
DEP domains (named after Dishevelled, Egl-10 and pleckstrin) are domains of 
unknown function that are found in a large number of proteins involved in the regulation of 
G protein signaling (13). They are evolutionary conserved and are found to occur in 
proteins from bacteria to mammals (14). The structure of the DEP domains of Dishevelled 
and Epac2 have been solved (14,15). These structures show that they have an unusual fold 
not found in other proteins in the structural database. It consists of three helices HI, H2 and 
H3, a 0-hairpin 'arm' between HI and H2 and two short (3-sheets following H3. The helices 
pack together to form the core of the structure that is stabilized by conserved hydrophobic 
contacts between the helices. The (3-hairpin 'arm' projects outward from the core and has a 
strong electric dipole associated with it. This (Winger 'arm' has been predicted to be 
involved in protein-protein interactions as this feature is common in protein-protein docking 
interfaces (14). Moreover, the DEP domains of P-Rex2 have also been shown to interact 
specifically with phosphorylated inositol lipids (Joseph, R.E and Norris, F.A., manuscript 
submitted). 
PDZ domains are involved in protein-protein interactions (16,17). They have been 
shown to bind to the C-terminal ends of membrane proteins or internal domains of proteins 
via a (3-hairpin structure. The crystal structure of several PDZ domains has been solved 
(18,19,20,21). It consists of -90 amino acids that fold into a globular structure with six (3-
sheets and two a-helices. Ligand binding occurs in the groove that is formed between the (3B 
strand and the ocB helix (16,17). PDZ domains were also referred to as 'GLGF' repeats due 
to a Gly-Leu-Gly-Phe repeat that was found between the (3A and |3B strands in most PDZ 
domains (16). The backbone amides from this sequence are involved in hydrogen bonding 
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with the free carboxylate residue and also serve to cap the peptide-binding grpove (16). The 
tandem arrangement of the two DEP domains and the two PDZ domains are retained in 
P-Rex 1 and both splice variants of P-Rex2 (Joseph, R.E. and Norris, F.A., manuscripts 
submitted). This suggests that they may be involved in the regulation of the GEF activity of 
these proteins. 
The GEF activity of the P-Rex family of proteins on Rac is conditional on the 
presence of phosphatidylinositol 3,4,5-trisphosphate or G (By subunits. However, the 
mechanism by which such exquisite control is mediated is not known (1). In this report we 
demonstrate that the inability of P-Rex2 to catalyze exchange on Racl is caused by its 
inability to bind Racl. The PDZ2 domain functions as an inhibitory domain by interacting 
with the (3304 loop of the PH domain and this interaction prevents Racl from interacting 
with P-Rex2. Deletion of PDZ2 domain is sufficient to restore Racl binding capability to 
P-Rex2. The PDZ domains also bind to the DEP domains of P-Rex2. Moreover, deletion 
constructs of P-Rex2 without the PDZ domains show enchanced activity in vivo. 
EXPERIMENTAL PROCEDURES 
Materials 
Wild type bacterial expression construct for RhoA was created by PGR amplification 
and cloned into the Smal/NotI sites of pGEX 4T-1 (Amersham Pharmacia Biotech). Bacterial 
expression constructs for Racl and Cdc42 were kind gifts from Gary Bokoch. The DH/PH 
domains of Dbl were PGR amplified from human mammary cDNA library (CLONTECH), 
and cloned into the pcDNA3.1D V5-His-TOPO vector (Invitrogen). The mammalian 
expression construct for full-length V5-tagged P-Rex2B was created by PGR using 
115 
oligonucleotdes 5 ' -CACCATGAGCGAGGACAGCCGCGGAGAC-3 ' (sense) and 
5'-GACAGGGGCCCTCTCTGCTAAG-3' (antisense) and ligated into the pcDNA3.1D V5-
His-TOPO vector. Myc-tagged full-length P-Rex2B was created by PGR using 
oligonucleotides 5'- CACCATGAGCGAGGACAGCCGCGGAGAC -3'(sense) and 5'-
TC AC AG ATCTTCTTC AGA AAT A AGTTTTTGTTCGAC AGGGGCCCTCTCTGCT A AG 
AG-3' (antisense) and ligated into the pcDNA3.1D V5-His-TOPO vector. The DH domain 
(residues 22 to 231), the PH domain (residues 241 to 370) and the DH/PH domains (residues 
22 to 370), DH/PH/DEP1 domains (residues 22 to 477), DH/PH/DEP1DEP2 domains 
(residues 22 to 574), DH/PH/DEP 1/DEP2/PDZ1 domains (residues 22 to 654), 
DH/PH/DEP 1/DEP2/PDZ1/PDZ2 domains (residues 22 to 762), DEP1DEP2 domains 
(residues 370 to 573) of P-Rex2 were cloned into pcDNA3.1D V5-His-TOPO vector by 
PCR. The (33(34 loop deletion mutant (amino acid residues 277 to 296) of the PH domain, and 
the bacterial expression construct for PDZ1 domain (residues 586 to 654) of P-Rex2were 
created by using the QuikChange™ Site-Directed Mutagenesis Kit from Stratagene, 
according to the manufacturers protocol. The bacterial expression construct for PDZ1PDZ2 
domains (residues 586 to 767), and PDZ2 domain (residues 654 to 767) was created by PCR 
amplification, digested with Notl and then ligated into pGEX4T-l cut with Smal and Notl. 
Expression and Purification of Proteins 
GST and GST-tagged Racl, RhoA, and Cdc42 were expressed and purified from 
Escherichia coli as described elsewhere (22). 
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Complex Formation Assay 
The complex formation assay was performed essentially as described (23). The 
deletion constructs of P-Rex2B were labeled with [35]S Met using rabbit reticulocyte lysate 
coupled transcription translation system (Promega) for 90min at 30°C in a total reaction 
volume of 10pA, as per the manufacturers instruction. 2p,l of this reaction was then incubated 
with 5|a,g of purified GST, GST-Racl, GST-RhoA or GST-Cdc42 in 500|il of complex 
formation assay buffer (20mM Tris pH 7.5; lOOmM NaCl; 2.0mM EDTA; 0.5%Triton X 
100) with 25p,l of glutathione sepharose beads (Amersham Pharmacia) for 2hrs at 4°C. The 
beads were spun down and washed five times with the same buffer. The beads were then 
boiled in SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE, followed by 
western transfer and autoradiography. 
Cell Culture and Membrane Ruffling Assay 
NIH 3T3 mouse fibroblast cells were plated on poly-lysine coated cover slips and 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf 
serum. The cells were transfected with expression plasmids encoding V5-tagged P-Rex2B, 
V5-tagged deletion constructs of P-Rex2B or GFP using Effectene (Qiagen), according to the 
manufacturers instructions. The cells were fixed 24 hrs post-transfection with 4% 
paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100, and then labeled with an 
anti-V5 or anti-GFP antibody to detect protein and Rhodamine phalloidin to detect 
filamentous actin as described earlier (23). Images were captured with a Spot RT digital 
camera (Roche Diagnostics) on a Nikon E800 microscope. 
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Immunoprecipitation Assay 
P-Rex2A and P-Rex2B were co-expressed and labeled with t35]S Met using rabbit 
reticulocyte lysate coupled transcription translation system (Promega) for 90min at 30°C in a 
total reaction volume of IOjliI, as per the manufacturers instruction. 4jli1 of this reaction was 
then incubated with anti-V5 antibody (1:500 dilution) in 500(0.1 of complex formation assay 
buffer (20mM Tris pH 7.5; lOOmM NaCl; 2.0mM EDTA; 0.5%Triton X 100) with 25|il of 
protein A beads (Sigma) for 2hrs at 4°C. The beads were spun down and washed five times 
with the same buffer. The beads were then boiled in SDS-PAGE sample buffer. The samples 
were analyzed by SDS-PAGE, followed by western transfer and autoradiography. 
RESULTS 
Presence of inhibitory domains in P-Rex2. 
P-Rex2A and P-Rex2B were shown to be Racl specific guanine nucleotide exchange 
factors that had an absolute requirement of either phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3) or G (By subunits for its activity (Joseph, RE. and Norris, F.A., manuscripts 
submitted). Moreover, the DH/PH domain of P-Rex2 was also demonstrated to specifically 
interact with Racl in a pull down assay (Joseph, R.E. and Norris, F.A., manuscript 
submitted). To determine whether full length P-Rex2 differed in its ability to interact with 
Racl, its binding property was tested using [3bJS Met labeled P-Rex2B. Surprisingly, full-
length P-Rex2B failed to interact with Racl (Fig. 1). Full-length P-Rex2A also failed to bind 
to Racl (data not shown). This suggested that there were inhibitory domain/s on the 
C-terminus of P-Rex2, which prevented its ability to interact with Racl. To determine the 
maximal sequence that retained the ability to bind Racl, a series of C-terminal deletion 
constructs were tested for their ability to bind Racl as before. As shown in Fig.2A and B, 
constructs lacking the PDZ2 domain of P-Rex2 were able to bind to Racl. This suggested 
that the PDZ2 domain made contact with the DH/PH domain of P-Rex2, and that this 
interaction could potentially block the ability of P-Rex2A and P-Rex2B to interact with 
Racl. 
The PDZ domains of P-Rex2 interact with the DEP domains ofP-Rex2. 
The domain architecture of P-Rex2B consists of an N-terminal DH/PH domains, 
followed by two DEP domains and two PDZ domains. While the function of DEP domains 
remains unknown, PDZ domains have been shown to be protein-protein interaction domains. 
PDZ domains have been shown to bind to the C-terminal ends of membrane proteins (18). 
Alignment of the PDZ domains of P-Rex2 with other PDZ domains show that they retain the 
conserved 'GLGF' motif found in most PDZ domains (Fig. 3A boxed residues). PDZ 
domains have also been shown to bind internal domains of proteins via a 3-hairpin structure 
(18). The structure of DEP domains showed that they have a (3-hairpin structure. The tandem 
arrangement of the two DEP domains and two PDZ domains in P-Rex2 suggested the 
intriguing possibility that the two PDZ domains may interact with the two DEP domains. 
Hence, the two PDZ domains were expressed and purified from bacteria, and tested for their 
ability to interact with [35]S Met labeled DEP domains. As shown in Fig.3B, the PDZ 
domains could indeed interact with the DEP domains. This is to our knowledge, the first 
demonstration of an interaction between these two classes of domains. The specificity of the 
interaction between the domains however could not be tested as the DEP domains could not 
be expressed individually either in bacteria or in reticulocyte 1 y sates. 
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The PDZ domains ofP-Rex2 interact with the PH domain of P-Rex2. 
Truncation analysis of P-Rex2 showed that deletion of PDZ2 domain is sufficient to 
restore Racl binding ability to the protein. Although the PDZ domains have been shown to 
interact with the DEP domains, it does not exclude the possibility of additional binding sites 
on the molecule. In order to determine the domain/s with which the PDZ domains interacted, 
it was expressed and purified from bacteria and tested for its ability to interact with deletion 
constructs of P-Rex2 that has been labeled as before. Surprisingly, as shown in Fig. 4A and 
B, the PDZ domains could interact with constructs that were lacking the DEP domains. The 
PDZ domains interacted with the DH/PH domains of P-Rex2, but not with the DH domain 
alone, suggesting that there were additional binding sites on the PH domain. To determine 
which PDZ domain interacted with the PH domain, the PDZ1 and PDZ2 domains were 
expressed individually and tested for their ability to interact with the PH domain. As shown 
in Fig. 4C, the PDZ1 and PDZ2 domains differ in their ability to interact with the PH 
domain, with the PDZ2 domain showing greater binding when compared to PDZ1 domain. 
The PDZ2 domain of P-Rex2 interacts with the J33/34 loop of the PH domain and competes 
with Racl binding. 
The 133(34 loop deletion mutant of the PH domain of P-Rex2 has been previously 
shown to lack Racl binding ability (Joseph, R.E and Norris, F.A., manuscript submitted). We 
tested the ability of the PDZ2 domain to interact with this deletion mutant. As shown in Fig. 
5A, the PH domain deletion mutant also fails to interact with the PDZ2 domain, suggesting 
that the binding site on the PH domain for Racl overlaps with that for the PDZ2 domain. To 
further evaluate this, we tested whether the PDZ2 domain would compete with Racl for 
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binding to the PH domain. As shown in Fig. 5B, increasing amounts of Racl diminished the 
ability of the PDZ2 domain to interact with the PH domain, suggesting that they bind to the 
same or overlapping sites on the PH domain. 
Intra-molecular interaction within P-Rex2. 
The inhibition of Racl binding by the interaction between the PDZ domains and the 
PH and DEP domains can be mediated via an intra or inter-molecular association. To 
distinguish between these two possible modes of interaction, an immunoprecipitation 
reaction was carried out. Full-length P-Rex2A and V5-tagged P-Rex2B were co-expressed in 
a reticulocyte lysate reaction as before. TheV5-tagged form of the protein was 
immunoprecipitated and tested for the presence of P-Rex2A. As shown in Fig. 6, P-Rex2A 
could not be co-immunoprecipitated with the V5-tagged form of P-Rex2B. This suggests that 
the interaction of the PDZ domain with the DEP and PH domains take place via an intra­
molecular interaction. 
Enhanced activity ofP-Rex2B truncation mutants in vivo. 
The PDZ domain truncation mutants of P-Rex2 were able to bind Racl in vitro. To 
determine whether these deletion mutants of P-Rex2 were constitutively active in vivo, they 
were transfected into NIH3T3 cells and the formation of membrane ruffles were assessed. As 
shown in Fig.7, deletion of the PDZ domains lead to approximately a two-fold increase in the 
percentage of cells with membrane ruffles, in the absence of stimulation. This is consistent 
with the ability of PDZ domain truncation mutants being able to bind Racl in vitro. 
Moreover, the DH domain alone was extremely poor at forming membrane ruffles (Fig. 7). 
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This is consistent with the inability of this domain to independently bind Racl in vitro 
(Joseph, R.E. and Norris, F.A., manuscript submitted). Deletion of the PDZ domain was 
however not sufficient to achieve full activation of P-Rex2 in vivo, as stimulation with PDGF 
led to a four-fold increase in membrane ruffles in P-Rex2 PDZ domain truncation mutant 
transfected cells. 
DISCUSSION 
Although Dbl family members are well conserved in the DH/PH domain, they share 
limited homology outside this region. They have been shown to possess a wide variety of 
other domains including SH2, SH3, PDZ, Ras-GEF, and additional PH domains (2). These 
domains have been shown to be involved in the coupling of GEFs to receptors and signaling 
molecules and also in regulating the activity of the GEF (2). The P-Rex family of proteins 
share a common domain architecture with a DH/PH domain, two DEP domains and two PDZ 
domains. The GEF activity of P-Rex proteins are conditional and require the presence of 
PtdIns(3,4,5)P3 and G(3y subunits (1, Joseph, R.E. and Norris, F.A., manuscripts submitted). 
Binding assays with full-length P-Rex2 show that the inactivity of the full-length P-Rex2 in 
the absence of effectors is in part due to its inability to bind Racl. The PDZ2 domain of 
P-Rex2 was shown to bind to the (33(34 loop of the PH domain via an intra-molecular 
interaction. This (33(34 loop of the PH domain has been shown previously to be the critical 
determinant for Racl recognition and specificity (Joseph, R.E. and Norris, F.A., manuscript 
submitted). Thus the region involved in Racl binding is at least partially or completely 
obscured by the PDZ2 domain. Movement of the PDZ2 domain away from the PH domain is 
thus one of the prerequisites for catalysis. Moreover, as the domain architecture of the P-Rex 
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family of proteins is conserved, it is possible that P-Rex 1 is also regulated in a similar 
manner. 
The PDZ domains of P-Rex2 are also involved in an interaction with the DEP 
domains. This is to our knowledge the first demonstration of an association between the DEP 
and PDZ modules. Interestingly, tandem DEP/PDZ domains are also found in other proteins 
like Dishevelled (24). Whether the DEP domains of other proteins also serve as a ligand for 
PDZ domains remains to be determined. The interactions between the DEP and PDZ 
domains may keep P-Rex2 inactive by further stabilizing the intra-molecular association 
between the PDZ2 domain and the PH domain. 
PDZ domains typically bind their ligands via a groove formed between the (3B strand 
and the ccB helix. However, the PDZ2 domain of P-Rex2 is involved in binding both the 
DEP1 domain and the PH domain. The interaction of the DEP domains with the PDZ 
domains is presumably mediated via an interaction between the P-hairpin arm of the DEP 
domains and the peptide-binding groove of the PDZ domains. Interestingly, the PDZ7 
domain of Glutamate receptor interacting protein 1 (GRIP1) was shown to interact with its 
ligand Ras guanine nucleotide exchange factor (GRASP 1) in a non conventional way 
involving a solvent exposed hydrophobic surface (25). The interaction between the PDZ2 
domain and the PH domain may involve such surface interactions. Thus, binding of the PH 
domain and DEP1 domain by the PDZ2 domain may involve both conventional binding 
through the groove and non-conventional surface interactions. 
Although the DH/PH domain of several Dbl family members have been extensively 
characterized, the properties of the full-length protein are less documented. Although 
effectors like phosphatidylinositol lipids have been shown to regulate the activity of the 
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DH/PH domain of several Dbl family GEFs like Vav, Sos and Tiaml, studies on full-length 
Dbl family GEFs show that they have additional modes of regulation (26,27). Dbl family 
members like Tiaml, Dbl, Asef and Vav have N-terminal inhibitory domains (28,29,30,31). 
N-terminal truncation mutants of these Dbl family GEFs are constitutively active when 
expressed in vivo (32,33). pll5RhoGEF and Lbc have C-terminal inhibitory regions (34,35). 
In most cases however, the mechanism by which such inhibition is brought about is not well 
understood (2). While C-terminal truncation mutants of P-Rex2 that lack the PDZ domain 
show enhanced activity in vivo, their activity can be further stimulated by PDGF. While this 
is consistent with an inhibitory role for these PDZ domains, it also suggests that additional 
changes are required for full activation of P-Rex2. The DH domain of P-Rex2 is incapable of 
binding Racl in vitro. Therefore, binding of PtdIns(3,4,5)Ps or G (By subunits by P-Rex2 may 
have a two fold effect: (1) movement of the PDZ2 domain away from the Racl interaction 
site on the PH domain and (2) conformational changes within the DH domain of P-Rex2 to 
make it catalytically competent. Future experiments will explore the details of the 
mechanism by which these effectors activate the P-Rex family of proteins. 
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FIGURE LEGENDS 
FIG. 1: Full-length P-Rex2B does not interact with Racl. Full-length P-Rex2B and the 
DH/PH domains of Dbl were labeled with [35]S Met and analyzed for their ability to bind to 
GST (negative control), GST-tagged Racl, RhoA or Cdc42 in a pull-down assay. The 
amount of bound protein was determined by western blotting and autoradiography. 
FIG. 2: The PDZ2 domain interferes with the ability of P-Rex2 to bind Racl. (A) 
Deletion constructs of P-Rex2 were labeled with [35]S Met and analyzed for their ability to 
bind to GST (negative control), GST-tagged Racl, RhoA or Cdc42 in a pull-down assay as 
before. (B) Schematic of the deletion constructs and summary of their Racl binding analysis. 
FIG. 3: The PDZ domains of P-Rex2 interact with the DEP domains. (A) Alignment of 
the PDZ domains of P-Rex2 with other PDZ domains. The conserved 'GLGF' motif is 
boxed. (B) The PDZ1PDZ2 domains of P-Rex2 were labeled with [35]S Met and analyzed for 
their ability to bind to GST (negative control), GST-tagged DEP1DEP2 in a pull-down assay 
as before. 
FIG. 4: The PDZ domains of P-Rex2 interact with the PH domain. (A) Deletion 
constructs of P-Rex2 were labeled with [35]S Met and analyzed for their ability to bind to 
GST (negative control) or GST-tagged PDZ1PDZ2 in a pull-down assay as before. (B) 
Schematic summary of the binding assays. (C) The PH domain of P-Rex2 was labeled with 
[35]S Met and analyzed for its ability to bind to GST (negative control), GST-tagged PDZ1 or 
PDZ2 in a pull-down assay as before. 
FIG. 5: The PDZ2 domain binds the (33(34 loop of the PH domain and interferes with 
Racl binding. (A) The WT PH domain or (33(34 loop deletion construct of the PH domain 
were labeled with [351S Met and analyzed for their ability to bind to GST (negative control), 
GST-tagged PDZ2 in a pull-down assay as before. (B) Racl competes with PDZ2 in binding 
to the PH domain. Racl and the PH domain of P-Rex2 were labeled with [35]S Met and 
analyzed for their ability to bind to GST (negative control), GST-tagged PDZ2 in a pull­
down assay as before. 
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FIG. 6: P-Rex2A and P-Rex2B do not form heterodimers. P-Rex2A and V5-tagged 
P-Rex2B were co-labeled with [351S Met as before. Immunoprecipitation of the V5-tagged 
P-Rex2B does not co-immunoprecipitate P-Rex2A. 
FIG. 7: Deletion of the PDZ domains of P-Rex2 leads to enhanced activity in vivo. NIH 
3T3 cells were transfected with V5-tagged P-Rex2 deletion constructs and assessed for the 
formation of membrane ruffles under the following conditions: (1) Untransfected cells, (2) 
DH domain, (3) DH/PH domain, (4) DH/PHDEP1,2 domains, (5) DH/PHDEP1,2PDZ1,2 
domains, (6) DH/PHDEP1,2 with PDGF stimulation. Data shown is the average obtained by 
counting fifty cells from two independent experiments. 
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GENERAL CONCLUSIONS 
SUMMARY 
P-Rexl is an IP4P-like domain containing GEF for Rac. It was isolated from 
neutrophils where it plays a key role in stimulating the neutrophil oxidative burst. Its GEF 
activity was stimulated directly by PtdIns(3,4,5)P3 and G(3y subunits. However, the domain/s 
responsible for interacting with these effectors and the mechanism by which P-Rexl was 
regulated were not known (1). 
This work describes the cloning and characterization of P-Rex2 a homologue of 
P-Rexl. The gene for human P-Rex2 is located on chromosome 8 at q 13.1, organized into 41 
exons, spread across -290 kb of DNA. The transcript for P-Rex2 undergoes alternate splicing 
to generate two forms of the protein, P-Rex2A and P-Rex2B. P-Rex2A consists of 1606 
amino acids and has a complex domain architecture with an N-terminal DH/PH domains, two 
DEP domains, two PDZ domains and a C-terminal IP4P-like domain. P-Rex2B consists of 
979 amino acids and differs from P-Rex2A in that it lacks the C-terminal IP4P-like domain. 
Both P-Rex2A and P-Rex2B are Rac specific GEFs whose GEF activity is conditional on the 
presence of PtdIns(3,4,5)P3 or Gfiy subunits both in vitro and in vivo. The PH domain of 
P-Rex2 was able to bind to these effectors. Moreover, the DEP domains of P-Rex2 was also 
able to interact with phosphorylated inositol lipids. The P-Rex family of proteins may 
therefore be Rac specific GEFs that integrate signals from both heterotrimeric G proteins and 
PI3Ks. 
Despite its similarity to IP4Ps, P-Rex2 did not hydrolyze any of the substrates we 
tested (PtdIns(3)P, PtdIns(4)P, PtdIns(3,4)P2, PtdIns(3,5)P2, PtdIns(4,5)P2, Ins(l,3,4)P3, 
Ins(l,3,4,5)P4 and pNPP). P-Rexl has also been previously reported to not hydrolyze 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 and pNPP (1). A closer look at the CX5R putative active 
site motif shows that the P-Rex proteins fail to maintain the IP4P consensus sequence of 
"CKSA/GKDR". The CX5R motifs of P-Rexl and P-Rex2A also differ from each other. 
Since this motif is present in protein phosphatases as well, the P-Rex proteins could very well 
be a protein phosphatase. Moreover, since the GEF activity of these proteins is under tight 
regulation by effectors, it is possible that its phosphatase activity is also under similar 
control. Comparison of the GEF activity of P-Rex2A and P-Rex2B shows that the 
phosphatase domain does not influence the ability of P-Rex2 to catalyze exchange in vitro. 
Furthermore, it does not influence the ability of Racl to form membrane ruffles in vivo. As 
Racl activation is involved in regulating other cellular processes like migration and oxidative 
burst, the ability of the phosphatase domain to influence these processes remain to be 
evaluated. 
Dbl family GEFs vary widely in their substrate specificity (2). Determination of how 
such specificity is achieved has been the focus of investigation recently (2,3). The Trp 56 
within the (32(33 strand region of Rac conferred Rac specificity as this residue was engaged 
by a conserved lie residue within the DH domain of Rac specific GEFs (2,4). Mutation of 
this Trp residue to Phe (the corresponding residue in Cdc42) was sufficient to prevent 
binding by the Rac specific GEF Tiaml (4). Based on the experiments presented in Chapter 
Four, it was found that P-Rex2 failed to conform to these predictions. Surprisingly, it was the 
PH domain of P-Rex2 that conferred substrate specificity and recognition. The PH domain of 
a Dbl family member had previously never been documented to perform this function. 
Specifically, the (33(34 loop region of the PH domain was necessary and sufficient for Racl 
recognition. Moreover, the corresponding interface on Racl that was being recognized by 
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this PH domain included the switch loop and helix 3 of Racl. The DH domaiy of P-Rex2 was 
not capable of interacting with Racl, suggesting that conformational rearrangements would 
be necessary for it to catalyze exchange on Racl. 
The results from Chapter Five give us an insight into the three dimensional 
architecture of P-Rex2. Full-length P-Rex2 is unable to bind its substrate Racl. An intra­
molecular interaction between the PDZ domains, the DEP domains and the PH domain, 
obscures the Racl binding site within P-Rex2. Deletion of the second PDZ domain was 
sufficient to restore Racl binding capability to P-Rex2. Furthermore, the second PDZ domain 
competes with Racl in binding to the PH domain of P-Rex2. Thus, this provides a partial 
explanation for the inactivity of full-length P-Rex2 on Racl. Moreover, it is also the first 
time that an interaction between a PDZ domain and a DEP domain has been documented. 
It becomes evident from summarizing the previous results that the GEF activity of 
P-Rex2 revolves around the PH domain. It is the domain that is responsible for recognizing 
the substrate Racl. Moreover, it keeps the protein inactive by an intra-molecular interaction 
with the second PDZ domain. Activation of this protein requires the presence of 
PtdIns(3,4,5)P3 or Gffy subunits, and the PH domain has been documented to bind to both of 
these effectors. Future experiments will determine the mechanism by which these effectors 
are able to activate P-Rex2. The PH domain of P-Rex2 is thus unique, serving a multi­
functional role and has thus stepped away from under the shadows of its cousins which serve 
mostly as mere membrane targeting devices. 
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BIOLOGICAL IMPLICATIONS 
Cellular processes are under tight regulatory control. Biological diseases are often a 
manifestation of the deregulation of some critical functions within the cell (5,6). Thus, an 
understanding of the proteins that regulate these processes will be key to our ability to 
intervene and manipulate these processes. P-Rexl plays a key role in stimulating the 
neutrophil oxidative burst by activating Rac a component of the NADPH oxidase complex 
(1). The characterization of P-Rex2 revealed that the P-Rex family of proteins are Rac 
specific GEFs that are tightly regulated by PtdIns(3,4,5)Pg and G(3y subunits. These proteins 
therefore provide a novel way to integrate signals from both heterotrimeric G proteins and 
PI3Ks. Furthermore, P-Rexl and P-Rex2A are the only two proteins in the database that have 
a Rho GEF domain along with an IP4P-like domain. The IP4P-like domain of these proteins 
may provide another way to link phosphoinositide metabolism to Rac activation in the cell. 
Characterization of P-Rex2 has revealed several new aspects about the domains 
within P-Rex2. Although DEP domains of several proteins have shown to be involved in 
membrane targeting, the in vivo ligands for these domains were unknown (7). The DEP 
domains of P-Rex2 were shown to interact specifically with phosphoinositide lipids. It is 
feasible that the DEP domains of other proteins can also interact with these lipids and 
mediate membrane localization. The DEP domains of P-Rex2 were also able to bind to the 
PDZ domains. This is the first instance where such an interaction between these two domains 
has been seen. Tandem DEP-PDZ domains are present in several other proteins in the 
database. Future experiments will uncover whether such interactions take place in other 
proteins. 
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The contribution of the PH domain of a Dbl family GEF in determining substrate 
specificity had never been investigated. P-Rex2 is the first member of Dbl family to achieve 
this function via its PH domain. This interaction between the PH domain and GTPases 
increases the number of ways in which specificity can be achieved. Moreover, this kind of 
interaction may be more widespread and could occur in other Dbl family members. The Rac 
specific GEF Trio is a prime example. The activity of the DH/PH domain of this protein is 
-100 fold higher than that of the DH domain alone (8). In light of the results obtained with 
P-Rex2, it will be interesting to determine whether the PH domain of Trio also interacts 
independently with Rac. 
Dbl family GEFs are often regulated by N and C-terminal sequences (9). Binding 
studied with full-length P-Rex2 showed that it is regulated by a C-terminal inhibitory 
sequence. The intra-molecular interaction between the second PDZ domain and the PH 
domain obscures the Racl binding site on P-Rex2, thus preventing P-Rex2 from catalyzing 
exchange on Racl in the absence of the effectors. Since the domain architecture of P-Rex2 is 
identical to that of P-Rexl, it is feasible that P-Rexl is also regulated by this mechanism. 
Moreover, like in the case of P-Rex2, the PH domain of P-Rexl may also be able to interact 
with both the effectors. 
FUTURE DIRECTIONS 
Although P-Rex2 has been extensively characterized in vitro, its biological function 
still remains unknown. The transcripts for both P-Rex2A and P-Rex2B are abundant in 
skeletal muscle tissue. Intriguingly, a non-phagocytic oxidase complex has been identified in 
skeletal muscle tissue (10). It has been suggested that the superoxide radicals generated by 
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this complex may be a part of a normal signal transduction pathway in these tissues, much 
like nitric oxide signaling (11,12). Future experiments will determine the role of P-Rex2 in 
regulating this complex. 
Deletion analysis of P-Rex2 has revealed the presence of C-terminal inhibitory 
sequences. Although deletion of the second PDZ domain is sufficient to restore Racl 
binding, the ability of these truncation mutants to catalyze exchange on Racl have not been 
evaluated. Activity assays with these truncation mutants done in the presence and absence of 
the effectors will provide valuable information regarding (1) the minimal unit required for 
catalysis, (2) the domain/s required for activation by the effectors and (3) the mechanism of 
activation by the effectors. Activity assays with full-length protein having point mutations 
within the PH domain or the DEP domains which effect lipid binding will give information 
regarding the relative contribution of these domains in regulating GEF activity. 
P-Rex2 is any structural biochemists' delight! The domains within P-Rex2 are 
involved in a plethora of novel interactions. The DEP domains and the PDZ domains are 
small and express easily in E. coli. They are therefore ideally suited for structural probing by 
either NMR or X-ray crystallography. The PH domain of P-Rex2 expresses well in Sf9 cells. 
Analysis of the binding between Racl and the PH domain can be done using 15N labeled 
protein by NMR. These studies will further extend the mutagenesis studies performed in 
Chapter Four. 
Identification of the substrate of the IP4P-like domain is by far the toughest project. 
Brute force methods like over-expression of dominant negative/active mutants of P-Rex2 are 
unlikely to succeed as (1) unavailability of such mutants, (2) due to the conditional nature of 
the activity of this protein, and (3) the fact that its substrate could be a protein or a lipid. It is 
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therefore imperative to gain a clear understanding of the biological role for thjs enzyme. This 
could then potentially be used as readout to assess the effect of deletion of the IP4P-like 
domain. Antibodies generated against both forms of P-Rex2, gene knockout or RNAi 
strategies will aid in our exploration of the in vivo function of P-Rex2. 
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